Pacific Edge Delivers on Growth Strategy in FY 2023

Company Announcement
25 May 2022
1


AUDITED FINANCIAL RESULTS FOR THE YEAR TO 31 MARCH 2023
PACIFIC EDGE DELIVERS ON GROWTH STRATEGY IN FY 2023
FINANCIAL AND PERFORMANCE HIGHLIGHTS:
• Annual operating revenue increases 71% to $19.6 million; total revenue increases 88% to $26.1 million
lifted by a 39% rise in commercial test volumes and favorable currency movements.
• Total laboratory throughput (TLT) of Cxbladder tests increases 37% to 31,565 tests, commercial tests
increase 39% to 26,691 tests; US ordering clinicians grow 46% to 1,150 at the end of Q4 23
• Net loss after tax increases to $27.0 million from $19.8 million, reflecting a 58% increase in operating
expenses to $53.1 million as the company invested to drive growth.
• Pacific Edge is well funded; cash and cash equivalents and short-term deposits at $77.8 million from $93.5
million at the end of September 2022 and $105.4 million at the end of March 2022

STRATEGIC HIGHLIGHTS:
• Diversified commercial roles, creating specialized sales roles and increasing headcount across commercial
teams; updated sales process to meet the needs of different customer types; scaling largely complete for
announced strategic initiatives
• Established medical education program; scientific and medical communications to support sales and
marketing efforts; reconfigured the clinical evidence generation program within the analytical validity (AV),
clinical validity (CV) and clinical utility (CU) framework to focus on retaining coverage and inclusion in
guidelines
• New product enhanced with DNA biomarkers, Cxbladder Detect
+
, developed as a single product for
hematuria evaluation
• FY 24 focus on execution – growth catalysts include clarity on Medicare coverage, the ‘go-live’ of the Kaiser
Permanente Electronic Medical Records (EMR) integration and the maturation of the new sales force

DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today announces financial and
operational results for the year to 31 March 2023 and reports a year of delivery on its strategic goals.
Through FY 23 Pacific Edge has advanced initiatives to drive the adoption and more frequent use by clinicians of
Cxbladder, the company’s suite of advanced genomic tests, and generate clinical evidence to support Cxbladder
coverage and the inclusion of the tests in global standards of care.
Operating revenue, the income generated from Cxbladder test sales, increased 71% to $19.6 million from $11.4
million in the prior financial year. Revenue growth followed a 39% increase in commercial tests to 26,691 from
19,196 tests in the prior year, with US commercial test numbers growing 46% to 23,072 from 15,752 for FY 22.
Favorable exchange rate movements also positively impacted FY 23 operating revenue. Without this favorable
movement, operating revenue increased 55% on FY 22.
As reported in Pacific Edge’s Q4 shareholder update in April, total test volumes for FY 23 rose to 31,565, a 37%
increase on the 23,086 tests processed in FY 22. Total revenue, which includes government grants and other
income, increased 88% to $26.1 million from $13.9 million in the prior financial year assisted by higher interest
income, up $2.2 million to $2.8 million and foreign exchange gains, up $2.1 million to $2.3 million.
The net loss after tax increased to $27.0 million, from $19.7 million in the prior year. This result followed a 58%
increase in net operating expenses to $53.1 million from $33.7 million in the prior year as the company invested in

Company Announcement
25 May 2022
2

growth, particularly in the US market. While exchange rate movements have increased reported revenue from the
US, expenses in the US were also increased due to these movements. Removing the impact of the exchange rate
movements, underlying operating expenses increased 47%.
These increased expenses reflected the expansion of the company’s global team including direct sales, marketing
and sales support teams and the introduction of new Medical Affairs and Market access capabilities to the business.
Investment in people accounted for 52% of operating expense growth. The company has now largely completed
scaling for its next phase of growth.
Pacific Edge retains a strong balance sheet with cash, cash equivalents and short-term deposits at 31 March 2023
of $77.8 million, compared to $93.5 million at the end of September 2022 and $105.4 million at the end of March
2022.
Chairman Chris Gallaher said: “Pacific Edge has successfully executed on the strategic priorities we outlined to
investors a year ago to drive the adoption of Cxbladder and to work towards the entrenchment of our tests as a
global standard of care for bladder cancer.
“Our efforts have been rewarded with a strong increase in commercial test volumes in the US, our most important
market; increased Cxbladder adoption by US clinicians and a significant improvement in operating revenues.
Following the introduction of new capabilities and the building of the team to the point that we are able to deliver
on the next phase of growth, Pacific Edge is well positioned to accelerate this momentum in the current financial
year.
“Our successes have been tempered by the ongoing lack of clarity over Cxbladder’s continued coverage by
Medicare. While unlikely, an unfavorable final version of the LCD has the potential to significantly reduce revenue
from patients with Medicare and Medicare Advantage insurance plans. Still, with cash reserves of $77.8 million we
are well positioned to execute on the significant opportunities we see, whatever the Medicare outcome,” Mr
Gallaher said.
Chief Executive Dr Peter Meintjes said the 2023 financial year had been one of enormous change and achievement
for the company.
“I am immensely proud of what we have achieved over my first full financial year leading Pacific Edge. The team
has embraced change and the new approaches we are taking to drive the commercial success of the company in
the US, our most significant market, and around the world.
“We have scaled the global team to execute on the immediate opportunities with new hires in direct sales,
marketing, and sales support. We have brought in new capabilities, including the recruitment of a Medical Affairs
team, which is tasked with engaging the urological opinion leaders that exert significant influence over the adoption
of Cxbladder tests by healthcare providers and payors. The team is also at the heart of our strategy to embed
Cxbladder in global standards of care, notably playing a key role in the design and execution of the clinical evidence
program that is foundational to that goal.
“We have enhanced our Market Access capability to drive coverage and reimbursement by national healthcare
providers and build resilience into our business in the face of complex healthcare regulatory and funding systems
in all the markets where we operate. We have also stepped up our business development capabilities in APAC and
introduced a variety of roles in digital technologies and innovation to support the company’s strategic growth plans.

Company Announcement
25 May 2022
3

“We have gained coding and coverage for Cxbladder Triage. We have developed Cxbladder Detect
+
, a new test
enhanced with DNA biomarkers that we are now advancing as a single product for hematuria evaluation. Cxbladder
Detect
+
delivers performance superior to our existing Triage and Detect tests and is well positioned to change the
standard of care.
“Pacific Edge is geared for growth. While the draft LCD from Novitas
1
has created some uncertainty, Cxbladder
remains a covered test by Medicare, and we have observed little impact on demand for Cxbladder from customers.
“Supported, however, by the advice and feedback we have received from our legal advisors, industry, academics
and clinicians and following numerous representations to Novitas, we remain optimistic that Cxbladder will retain
coverage,” Dr Meintjes said.
“We are looking forward to the deadline on July 28 when Novitas must either finalize or withdraw the proposed
Local Coverage Determination (DL 39365) and the associated Local Coverage Article (DA 59125) that cast
Cxbladder’s continued Medicare coverage into doubt.”
ADOPTION RETENTION AND REVENUE GENERATION
Our US business is making steady progress. US Total Lab Throughput (TLT) for the year was up 44% to 27,217 from
18,864 tests in FY 22. Commercial tests increased 46% to 23,072 from 15,752 in the prior year.
We are already seeing the benefits of expanding the direct sales force and creating differentiated commercial roles
to meet the needs of different customer types. We now have dedicated teams for national accounts, regional sales,
virtual sales and market access.
The Medical Affairs team has changed the narrative on biomarker utility in bladder cancer detection and patient
surveillance, driving increased engagement with key opinion leaders, department heads and the chairs at leading
institutions, or owners and partners at private practices.
The team is also driving clinical behavior change. This is most evident at Kaiser Permanente, our largest US customer
with an estimated 12.5 million members covered by its health plan. Pacific Edge is a valued innovation partner for
Kaiser Permanente, underpinned by our shared desire to reduce unnecessary cystoscopies during hematuria
evaluation and surveillance.
Adoption within Kaiser is growing steadily. Two of its clinics were in the top 20 Pacific Edge accounts by volume in
the last quarter. A catalyst of further acceleration in growth will be the ‘go-live’ of Cxbladder’s integration with
Kaiser’s EMR system. We have completed the software development and integration testing on the project and are
now focussed on completing the required administrative and review processes.
Our New Zealand business has delivered a steady performance. Our tests are available to more than 75% of New
Zealand’s population, but there remains an opportunity to drive the utility to primary care, to increase adoption
for hematuria evaluation among surveillance users and increase adoption for surveillance among hematuria
evaluation users.

1
Novitas is the Medicare Administrative Contractor with jurisdiction for our US laboratory,

Company Announcement
25 May 2022
4

Over the last year we added contracts with Te Whatu Ora Health New Zealand Southern District and expanded
coverage in Tairawhiti on the East Coast of New Zealand. The most significant catalyst in the New Zealand market
is an opportunity to expand access through a national contract with Te Whatu Ora.
The rest of the APAC market is in the early stages of development. We recently appointed a President APAC charged
with building on the company’s presence in Australasia in the broader APAC region. APAC TLT for the year rose 3%
to 4,348 from 4,222 tests in FY 22. Commercial tests increased 5% to 3,619 from 3,444 in the prior year.
Our strategic focus across both regions for the year ahead remains the same, although we are embarking on a new
range of digitalization and performance excellence initiatives to improve the effectiveness and efficiency of our
operations.
EVIDENCE COVERAGE AND GUIDELINES
We reviewed and reconfigured our evidence generation program. Our aim is to ensure it achieves our goals of
assisting the clinical adoption of Cxbladder and the inclusion of the tests in global standards of care. Clinical
evidence is also at the heart of our goals to foster trusted relationships with key urologic opinion leaders and
enhance the scientific credibility of the Cxbladder brand.
Our focus is on generating data to demonstrate the analytical and clinical validity and ultimately the clinical utility
2

of Cxbladder, including the new product Cxbladder Detect
+
. We have six key studies underway directed towards
these goals and have accelerated enrolment and site monitoring to drive the studies more rapidly towards
completion.
In the closing months of the financial year, we were pleased to gain Medicare coverage for Cxbladder Triage. This
followed the test’s inclusion in the Local Coverage Article (LCA 58917) that Pacific Edge currently relies upon for
Medicare coverage of all our tests in the US.
As signalled in April, we expect the development to lead to modest increases in rates of payment from Medicare
and Medicare Advantage payors for Triage. We also see coding and listing in LCA 58917 as a faster tangible path for
Cxbladder Detect
+
to gain coverage, should the current approach to reimbursement of our tests in the US continue.
Finally, we are now working to supplement our evidence generation program with investigator-initiated trials and
the establishment of a Cxbladder registry, where clinicians can record a wide range of patient data, including follow
up and outcomes. The registry, as it grows, becomes a multi-site, real-world evidence clinical trial. While clinical
utility trials are the gold standard for guidelines inclusion, and we expect many private payors to cover Cxbladder
after inclusion in guidelines, real-world evidence is frequently required by many private payors to drive medical
policy and subsequent contracting.
RESEARCH AND INNOVATION
The key success of our innovation team in FY 23 was the publication of evidence supporting the analytical validity
of Cxbladder Detect
+
in the prestigious Journal of Urology, which demonstrated significant improvements in test
performance. A key focus in the coming year will be to investigate the potential for a Monitor
+
product for
surveillance based on similar DNA SNPs. Our R&D team continue to evaluate product concepts to address unmet

2
For definitions of analytical and clinical validity and clinical utility please refer to page 45 of the investor presentation released
to the NZX and ASX today.

Company Announcement
25 May 2022
5

clinical needs in urology diagnostics, for example, our MONSTER study is aimed at identifying additional markers of
residual disease in surveillance patients.
OUTLOOK
Pacific Edge is building on the steady growth we have achieved in FY 23. We continue to invest prudently to improve
the effectiveness and efficiency of the team we now have in place, Dr Meintjes said. “The lack of clarity over
continued Medicare coverage continues to represent a headwind for the company, but we remain confident and
optimistic about our outlook. We have world-leading technology, a strong balance sheet and we are building
momentum in the US and establishing footholds in new markets.
“We also see the potential for several catalysts to drive our success in the coming year, including a positive Medicare
determination, the ‘go live’ of the Kaiser EMR integration, the growing maturity of our sales force and, locally, a
national contract with Te Whatu Ora. Longer-term we are looking to the publication of clinical utility evidence from
our studies and those conducted independently of Pacific Edge,” Dr Meintjes said.
“The entire Pacific Edge team is working hard to bring all of these catalysts to fruition, and we look forward to
providing an update to our shareholders at our annual meeting in Auckland at the end of July.”
Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.
For more information:
Investors Media
Dr Peter Meintjes Richard Inder
Chief Executive The Project
Pacific Edge P: +64 21 645 643
P: 022 032 1263

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialization of
bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered
in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories
in New Zealand and the USA.

About Cxbladder www.cxbladder.com
Cxbladder is a non-invasive genomic urine test optimized for the detection and management of bladder cancer. The Cxbladder evidence
portfolio developed over the past 14 years includes more than 20 peer reviewed publications for primary detection, surveillance, adjudication
of atypical urine cytology and equivocal cystoscopy. Cxbladder is the focal point of numerous ongoing and planned clinical studies to generate
an ever-increasing body of clinical utility evidence supporting adoption and use in the clinic to improve patient health outcomes. Cxbladder
is reimbursed by CMS and has been trusted by over 2,000 US urologists in the diagnosis and management of more than 80,000 patients,
including the option for in-home sample collection. In New Zealand, Cxbladder is accessible to 70% of the population via public healthcare
and all residents have the option of buying the test online.

---

Pacific Edge
FY 23 FINANCIAL RESULTS
Investor presentation
Dr Peter Meintjes
Chief Executive
25 May 2023
PacificEdge’sordinarysharestradeontheNZXand
theASXunderthetickercode:PEB

IMPORTANT NOTICE AND DISCLAIMER
ImportantNotice
This presentation has been prepared by Pacific Edge Limited (PEL) solely
to provide interested parties with further information about PEL and its
activities at the date of this presentation.
Information of a general nature
The information in this presentation is of a general nature and does not
purport to be complete nor does it contain all the information which a
prospective investor may require in evaluating a possible investment in
PEL or that would be required in a product disclosure statement,
prospectus or other disclosure documentfor the purposes of the New
Zealand Financial Markets Conduct Act 2013 (FMCA) or the Australian
Corporations Act 2001. PEL is subject to a disclosure obligation that
requires it to notify certain material information to NZX Limited (NZX)
and ASX Limited (ASX) forthe purpose of that information being made
available to participants in the market and that information can be found
by visiting www.nzx.com/companies/PEBand
www2.asx.com.au/markets/company/PEB.This presentation should be
read in conjunction with PEL’s other periodic and continuous disclosure
announcements released to NZXand ASX.
Not an offer
This presentation is for information purposes only and is not an
invitation or offer of securities for subscription, purchase or sale in any
jurisdictionwhere such offer purchase or sale would not be permitted.
Not financial product advice
This presentation does not constitute legal, financial, tax, financial
product advice or investment advice or a recommendation to acquire
PEL securities, and has been prepared without taking into account the
objectives, financial situation or needs of investors. Before making an
investment decision, prospective investors should consider the
appropriateness of the information having regard to their own
objectives, financial situation and needs and consult an NZX Firm,
solicitor, accountant or other professional advisor if necessary.
Forward-looking statements
This presentation may contain forward-looking statements that reflect
PEL’s current views with respect to future events. Forward-looking
statements, by their very nature, involve inherent risks and
uncertainties. Many of those risks and uncertainties are matters which
are beyond PEL’s control and could cause actual results to differ from
those predicted. Variations could either be materially positive or
materially negative. The information is stated only as at the date of this
presentation. Except as required by law or regulation (including the NZX
Listing Rulesand ASX Listing Rules), PEL undertakes no obligation to
update or revise any forward-looking statements, whether as a result of
new information, future events or otherwise. To the maximum extent
permitted by law, the directors of PEL, PEL and any of its related bodies
corporate and affiliates, and their respective officers, partners,
employees, agents, associates and advisers do not make any
representation or warranty, express or implied, as to the accuracy,
reliability or completeness of such information, or the likelihood of
fulfilment of any forward-looking statement or any event or results
expressed or implied in any forward-looking statement, and disclaim all
responsibility and liability for these forward-looking statements
(including, without limitation, liability for negligence).
Financial data
All dollar values are in New Zealand dollars unless otherwise stated. This
presentation should be read in conjunction with, and subject to, the
explanations and views of future outlook on market conditions, earnings
and activities given in the announcements relating to the results for the
12 months ended 31 March 2023.
Effect of rounding
A number of figures, amounts, percentages, estimates, calculations of
value and fractions in this presentation are subject to the effect of
rounding. Accordingly, the actual calculation of these figures may differ
from the figures set out in this presentation.
Past performance
Investors should note that past performance, including past share price
performance, cannot be relied upon as an indicator of (and provides no
guidance as to) future PEL performance, including future financial
position or share price performance.
Investment risk
An investment in securities of PEL is subject to investment risk and other
known and unknown risks, some of which are beyond the control of PEL.
PEL does not guarantee any particular return or the performance of PEL.
Disclaimer
None of PEL or PEL’s advisers or any of their respective affiliates, related
bodies corporate, directors, officers, partners, employees and agents,
have authorised, permitted or caused the issue, submission, dispatch or
provision of this presentation and, except to the extent referred to in
this presentation, none of them makes or purports to make any
statement in this presentation and there is no statement in this
presentation which is based on any statement by any of them.
To the maximum extent permitted by law, none of PEL and its advisers,
affiliates, related bodies corporate, nor their respective directors,
officers, partners, employees and agents makes any representation or
warranty, express or implied, as to the currency, accuracy, reliability or
completeness of information in this presentation; and none of them shall
have any liability (including for negligence) for:
•any errors or omissions in this presentation; or
•any failure to correct or update this presentation, or any other
written or oral communications provided in relation to this
presentation; or
•any claim, loss or damage (whether foreseeable or not) arising from
the use of any information in this presentation or otherwise arising in
connection with this presentation or the information contained in it.
By receiving this presentation, you agree to the above terms and
conditions.
2

FY 23 HIGHLIGHTS: BUILDING MOMENTUM CXBLADDER ADOPTION
FINANCIAL PERFORMANCE AND TEST VOLUMES
($27.0M)
NET LOSSAFTER
TA X
Global TLT of 31,565
US TLT increase 44% on FY 22
to 27,217 tests
Increase from ($19.8M) in
FY 22 amid investment for
future growth
Operating revenue $19.6M
To t a l re v e n u e o f $ 2 6 . 1 M u p
88% on FY 22
$77.8M
CASH, CASH
EQUIVALENTS
3
Strong Balance Sheet
$27.6M reduction in cash &
cash equivalents
3
on FY 22
39%
COMMERCIAL
TEST VOLUMES
on FY22
37%
1
GLOBAL TESTING
VOLUMES
(TLT
2
) on FY22
71%
GROWTH IN
OPERATING
REVENUE on
FY22
Commercial Tests of 26,691
US Commercial Tests rise
46% on FY 22 to 23,072
tests
1.All comparisons are to the same period in the prior year unless otherwise stated.
2.TLT is the Total Laboratory Throughput including commercial, pre-commercial and clinical studies testing
3.Cash, short-term deposits and term deposits
PACIFIC E DG E IS DE LIV E RING ON ITS ST RAT EGY
•ADOPTION, RETENTION & REVENUE GENERATION
•EVIDENCE, COVERAGE AND GUIDELINES
•RESEARCH AND INNOVATION
3

A YEAR OF STRATEGIC DELIVERY
SCALING FOR EXECUTION SUBSTANTIALLY COMPLETE, READY FOR THE NEXT PHASE OF GROWTH
ADOPTION,
RETENTION AND
REVENUE
GENERATION
EVIDENCE
COVERAGE AND
GUIDELINES
RESEARCH &
INNOVATION
•Test volumes in the key US market rise 44% in FY 23 to 27,217
•US ordering clinicians rise 46% to 1,150 from 789 in Q4 22; tests/clinician steady
•Diversified commercial roles (incl. Medical Affairs & Market Access); FTE +27 to 114*
•2 Kaiser Permanente accounts in PEB top 20; EMR technologically complete
•Reconfigured & expanded clinical studies framed by AV, CV & CU**, focused on guidelines
•Increased enrolment & site monitoring resources for STRATA and DRIVE for faster completion
•Coding & coverage established for Cxbladder Triage, laying a path for Cxbladder Detect
+
•Adding DNA SNPs to RNA products significantly improves performance: Cxbladder Detect
+
•Technology transfer and validation of Detect
+
to PEDNZ and PEDUSA labs (in progress)
•Investigating potential for a Monitor
+
product for surveillance based on similar DNA SNPs
4
*FTE count at 31 March 2023
**AV = Analytical Validity, CV = Clinical Validity, CU = Clinical Utility

BLADDER CANCER
A SIGNIFICANT GLOBAL HEALTHCARE CHALLENGE
1. World Cancer Research FundAnnual case figure is 2020.
2. American Society of Clinical Oncology Annual death figure is 2020.
3. Average recurrence for low grade cancer
4. International Agency for Research on Cancer
5
10
th
Most common
cancer world-
wide
1
~70%
Recurrence
3
~573K
Annual cases
and growing
1
>212K
Annual
deaths
2
6
th
Most common
cancer in men
1
17
th
Most common
cancer in women
1
<1.7 1.7 to 2.7 2.7 to 5.3 5.3 to 8.6 >8.6
INCIDENCE PER 100,000 OF THE POPULATION
4

1. Pacific Edge estimates
USA –To t a l A d d re s s a b l e M a r ke t ( TA M ) U S $ 3 . 5 b
Americas (non-US) –TA M US$ 0 .5 b
EMEA (w/o most of Africa) –TA M US$ 1 .4 b
APAC (w/o China) –TA M US$ 2 .2 b
US$7.6b
To t a l
Addressable
Market
1
6
CXBLADDER IS A GLOBAL OPPORTUNITY
•US is the focus of our growth efforts
•New Zealand is a mature market
•APAC in business development
•Distribution considered in other markets
on a case-by-case basis
GLOBAL COMMERCIALIZATION

PACIFIC EDGE AT A GLANCE: GROWING GLOBALLY
Commercial markets
Distribution partners
Markets with clinical study partnerships
USA
CANADA
Pacific Edge Diagnostics USA
Hershey, Pennsylvania
AUSTRALIA
NEW ZEALAND
SINGAPORE
Pacific Edge HQ, Dunedin
FROM IP DEVELOPMENT TO PATIENT
1.Company data
•IP: 4x patent families in bladder cancer, with >80 patents including RNA
biomarkers and their analysis algorithms
•Cxbladder: Advanced genomic biomarker tests from a non-invasive urine
sample for the early detection and management of bladder cancer
•Clinical Evidence: Peer-reviewed clinical validity and utility data that
shows Cxbladder outperforms Standard of Care (SoC)
•Reimbursement: Cxbladder tests reimbursed by Medicare and Kaiser
Health Plan in the USA
•Patient Empowerment: Non-invasive efficacious testing offers
opportunity for increased patient compliance with surveillance and
management regimes
>1,151
1
Unique ordering
clinicians in Q4 23
~300K
1
Annual
laboratory test
capacity
114
1
FTEs up 27 FTE
since the end of
Mar 22
7
ISRAEL

MONITOR FOR
RECURRENCE
SURVEILLANCE
(RDM
1
, TRM
2
, RECURRENCE)
PATIENT/DISEASE MANAGEMENT
(CLINICAL DECISION MAKING)
MOLECULAR DIAGNOSTICS VALUE CHAIN:
PATIENT JOURNEY
GENOMIC SCREENING
(PERSONALIZED GENETIC RISK)
ASYMPTOMATIC SCREENING
(EARLY DETECTION)
1.RDM: Residual Disease Monitoring
2.TRM: Therapeutic Response Monitoring.
8
INTENSIFY/DE-INTENSIFY
WORKUPS
ADJUDICATEDIAGNOSTIC
DILEMMAS
SURGICAL OR
THERAPEUTIC
INTERVENTION
SYMPTOMS
ONSET
GENETIC RISK
AT BIRTH
DISEASE
MANIFESTS

PATIENT CARE PATHWAY: VALUE PROPOSITION
Primary Care Physician
Patient presents with
hematuria and clinician
cannot rule out cancer.
Patient referred to
urologist
Urologist/Specialist
Current guidelines for
hematuria evaluation
recommend ~95%get
cystoscopy
1
ahead of
diagnosis & treatment
Urologist/Specialist
Monitor for recurrence
with cystoscopy,
frequency varies
according to patient
presentation
Typical
standard of
care on the
patient care
pathway
For use by
SPECIALISTS to detect
the presence of
urothelial cancer and
adjudicate diagnostic
dilemmas
For use in the PRIMARY CARE and SPECIALIST
settings to de-intensify hematuria workup or rule out
urothelial cancer (UC)
For use by SPECIALISTS
to monitor for recurrence
at a frequency proportional
to risk
TRIAGE
DETECT
MONITOR
Cxbladder
TRIAGE
Cxbladder
DETECT
Cxbladder
MONITOR
VALUE PROPOSITION
Assists clinicians to safely de-intensify
hematuria evaluation from low incidence
populations
Sensitivity 95% / NPV 99%
Assists clinicians to adjudicatediagnostic
dilemmas (e.g., equivocal cystoscopy &
atypical cytology) in any patient population
Sensitivity 82% / Specificity 85% / NPV 97%
Assists clinicians in monitoring for UC
recurrence. Intended to reduce the
frequency of surveillance cystoscopy and
improve patient compliance
Sensitivity 93% / NPV 97%
Sensitivity: the likelihood of the test to be positive in a patient with the disease Specificity: the likelihood of the test to
be negative when the patient does not have the disease; NPV: the likelihood of a negative test being a true negative.
1
AUA Guidelines and Woldu SL, Ng CK, Loo RK, Slezak JM, Jacobsen SJ, Tan WS, et al. (2021a). "Evaluation of the New American Urological Association Guidelines
Risk Classification forHematuria."JUrol205(5): 1387-1393.
9

BLADDER CANCER IN THE US MARKET
90%
Five-year survival
rate for NMIBC if
detected early
1
US$191K
Average lifetime
cost per patient
2
US$9.4B
Annual US spend on
bladder cancer
3
The US has >55m
men and >63m
women aged 50+
~7m
present with
hematuria
4
~3.4m
referred for
clinical
workup
4
>1.0m
patients
receive a
cystoscopy
5
~82k
Annual cases of
bladder cancer
6
~725k
patients living with
bladder cancer
~1.5CxbMonitor/yr
6
US$3.5B
opportunity
7
(hematuria,
surveillance)
1. Bladder Cancer Advocacy Network
2. Aly A et al. (2020) The Real-World Lifetime Economic Burden of Urothelial Carcinoma by Stage at Diagnosis. J Clin Pathw. 2020 May; 6(4):51-60
3. National Cancer Institute: Cancer Progress Trends Report
4. Presentation from Dr Sia Daneshmand(Director of Urologic Oncology and Clinical Research, USC) July 2019
5. Kenigsberg, A, et al. The Economics of Cystoscopy: A Microcost Analysis, Urology 157: 29−34, 2021.
6. National Cancer Institute
7. Pacific Edge Estimate, opportunity estimated at US$760/Per test
VALUE PROPOSITION
Primary Care Physician
Urologist/Specialist
Patient care
pathway
Cxbladder
TRIAGE
Cxbladder
DETECT
Cxbladder
MONITOR
10
>4.5M TESTOPPORTUNITIES

OUR STRATEGY TO DRIVE LONG TERM GROWTH AND VALUE CREATION
OUR PEOPLE
OUR PROCESSES
OUR IP, KNOWLEDGE
AND EXPERIENCE
OUR CLINICAL STUDIES
PARTNER SITES
OUR INVESTORS
EARLY DETECTION AND
CLINICALLY ACTIONABLE CARE
INNOVATION PIPELINE FOR
CLINICAL APPLICATIONS
INCLUSIVE WORKPLACE
DRIVEN BY OUTCOMES
INCREASED LONG-TERM
SHAREHOLDER VALUE
ADOPTION,
RETENTION AND
REVENUE
GENERATION
EVIDENCE,
COVERAGE AND
GUIDELINES
RESEARCH
AND
INNOVATION
A DIVERSE AND INCLUSIVE VALUES-DRIVEN CULTURE WHERE ALL EMPLOYEES CAN GROW AND THRIVE.
OUR FOUNDATIONS
EXCELLENT PATIENT EXPERIENCE
AND ACCURATE RESULTS
INPUTSOUTPUTS
11

ADOPTION, RETENTION AND REVENUE GENERATION
FOCUS AREAS:
1.Pursue structured sales process based on customer type
supported by efficient digital architecture; engage KOLs with
medical education and communication
2.Drive protocolized adoption of Cxbladder through patient use
cases highlighting utility at the earliest point in patient care
3.Amplify our clinical evidence generation program within the
urology and oncology communities with marketing,
sponsorship and our medical affairs teams
4.Establish medical policy, then contracting for reimbursement
by government and private payors; accurately documenting
‘medical necessity’ to improve payment objectives
5.Empower patients through patient awareness and patient
advocacy initiatives through established societies and our
Cxbladder website
6.NEW: Internal digitalization and Performance Excellence
(PerfEx) initiatives to improve the effectiveness and
efficiency of our operations
ADOPTION,
RETENTION AND
REVENUE
GENERATION
12

EFFECTIVE INVESTMENTS FOR GROWTH: DIRECT SALES AND MARKETING
INVESTMENTS FOR GROWTH
DIRECT SALES:
-New Direct Sales hires -Account Executives, Regional Sales Directors, National Accounts & Virtual Sales
(contractors) +9 FTE* taking total to 37 FTE.
ACHIEVEMENTS:
-Diversified role types and created specializing sales roles and responsibilities
-National Accounts, Regional Sales, Virtual Sales, MSLs and Market Access
-Standardising our sales process across customer types
-Established collaboration with Medical Affairs on education events focus on communicating clinical evidence
-Improved our US geographic coverage in urban areas; leveraging virtual teams and PIHSS for under-served rural
areas
MARKETING AND SALES SUPPORT:
-New hire in Event Management, Sales Training & Sales Operations +3 FTE*taking total to 4 FTE
ACHIEVEMENTS:
-Improved customer targeting and key opinion leader (KOL) identification
-Improved new hire training and refresher training to focus on patient use cases
-Supported a program of >50 urologic conferences/year (podiums, presentations, and PI Meetings)
-Enhanced our advertising, patient outreach, advocacy (UroToday, Urology Time, BCAN, New Zealand Cancer
Society)
-Improved internal communications and employee engagement
* All staff counts are 31 March 2022 vs31 March 2023
13

EFFECTIVE INVESTMENTS FOR GROWTH: MARKET ACCESS AND MEDICAL AFFAIRS
INVESTMENTS FOR GROWTH
MEDICAL AFFAIRS:
-Chief Medical Officer, Medical science Liaisons and full-time US-based clinical trial monitors +7 FTE
ACHIEVEMENTS:
-Established a highly credible medical education program; scientific and medical communications to support sales,
marketing efforts (alongside efforts to develop evidence, gain coverage and be included in guidelines)
-Increased engagement with Key Opinion Leading (KOL) physicians and institutions (National Accounts)
-Established a framework for US-led IITs, Registries and Research Partnerships
-Aligned clinical development, patient enrolment, clinical trials monitoring and medical affairs
education/communication
MARKET ACCESS AND REIMBURSEMENT:
-VP Market Access +1 FTE (taking total to 2)
ACHIEVEMENTS:
-Continuous improvement for Cxbladder ordering process and documentation for establishing medical
intent/necessity
-Improved documentation processes for ‘medical necessity’ – a requirement for Medicare coverage
-Distribution agreement with Israel’s ProGenetics (supported by PEDUSA)
-Industry collaboration and representations to Novitas to drive clarity on continued Medicare coverage (current LCD)
-Coding and coverage achieved for Cxbladder Triage, establishing a potential path for Detect+
14
*All staff counts are 31 March 2022 vs. 31 March 2023,headcount increase to 114 FTE includes ~12 additional FTE in laboratory, support and finance and back office
and a new APAC President

8,147
6,864
11,136
14,920
8,714
8,950
11,950
16,645
-
5,000
10,000
15,000
20,000
25,000
30,000
35,000
FY20FY21FY22FY23
TESTS
2H
1H
6,573
5,591
9,192
12,422
7,054
7,385
10,004
14,269
-
5,000
10,000
15,000
20,000
25,000
30,000
FY20FY21FY22FY23
TESTS
2H
1H
19%
56%
25%
17%
61%
22%
GLOBAL: COMMERCIAL TESTS GROWING STRONGLY AS US ACCELERATES
FY 22
TEST VOLUMES BY TYPE (TLT*)
GLOBAL COMMERCIAL TEST VOLUMES (TLT*)
GLOBAL TEST VOLUMES (TLT*)
FY 23 Total Lab Throughput (TLT)
•Global TLT increased 37% to 31,565 tests
•Global Commercial test volumes increased 39% to 26,691
•Global TLT is driven by US growth in the US (predominantly Detect)
•Hematuriaevaluation (Triage & Detect) is the larger market
opportunity, ~3x the size of bladder cancer surveillance (Monitor)
23,086
15,814
16,861
*TLT is the Total Laboratory Throughput including commercial, pre-commercial and clinical studies testing
FY 23
▲
39%
▲
37%
31,565
19,196
12,976
13,627
26,691
15

2,133
2,791
3,110
3,824
4,277
4,706
4,591
5,290
6,073
6,699
6,629
7,816
-
1,000
2,000
3,000
4,000
5,000
6,000
7,000
Q1 21Q2 21Q3 21Q4 21Q1 22Q2 22Q3 22Q4 22Q1 23Q2 23Q3 23Q4 23
Test volume
▲
43%
CAGR
2
STRONG GROWTH IN THE US: PACIFIC EDGE’S LARGEST MARKET
US GENERATING ~86% OF TOTAL TEST VOLUME
1
USA TEST VOLUMES
1
1
Total Laboratory Throughput including commercial, pre-commercial and clinical studies testing
2
CAGR compares Q4 21 to Q4 23
Commercial tests represent 85%of FY 23 TLT in the USA
FY 23 PROGRESS WITH THE LARGEST US PAYORS
The Kaiser Health Plan covers >12.5m members
•2 Kaiser sites in PEB’s Top 20 Accounts. 14 Kaiser sites
across Southern California ordering in FY23
•EMR software development and integration testing
complete; KP and PE working towards “go live”
The Veterans Administration serves >9m veterans each year
•DRIVE clinical study, has enrolled 80% of target patients
•DRIVE is a key engagement with VA urologists to
determine clinical validity in a cohort of VA patients
Medicare covers >61.5m US citizens over 65
•Cxbladder has a majority Medicare and MA population;
average age of 73 for presentation with hematuria
•Medicare and MA represent ~20% of the population, but
~60% of US commercial tests for Cxbladder
•Pacific Edge’s Medicare Administrative Contractor
Novitas continues to reimburse at US$760/test, but the
proposed LCD creates some uncertainty
16

DIGITALIZATION & ‘PERFEX’ INITATIVES TO SIMPLIFY CLINICIAN ORDERING
UNIQUE US CLINICIANS ORDERING CXBLADDER
▲
47%
CAGR
1
‘STICKINESS’ AND CUSTOMER EXPERIENCE INITIATIVES
1.Commercially-led product management for end-to-end
customer experience, supported by digital workflows
2.EMR integrations and Customer Portal
FIT FOR GROWTH/DIGITALIZATION
1.Investment to upgrade older hardware and IT systems
2.EMR integrations and Customer Portal (as above)
3.Performance Excellence: Lab Operations and Customer
Service
17
1
CAGR compares Q4 21 to Q4 23
411
462
516
530
657
690
741
789
895
978
1,082
1,150
-
200
400
600
800
1,000
1,200
1,400
Q1 21Q2 21Q3 21Q4 21Q1 22Q2 22Q3 22Q4 22Q1 23Q2 23Q3 23Q4 23
CLINICIANS

852
1,088
943
1,073
1,079
1,074
1,117
952
983
1,165
1,139
1,061
-
200
400
600
800
1,000
1,200
1,400
Q1 21Q2 21Q3 21Q4 21Q1 22Q2 22Q3 22Q4 22Q1 23Q2 23Q3 23Q4 23
Test volume
APAC: NEW ZEALAND AT THE FOREFRONT WITH ADOPTION BY PRIMARY CARE
APAC GENERATING ~14% OF TEST VOLUME
1
Commercial tests represent 83%of TLT in FY 23 for APAC
APAC TEST VOLUMES
1
1
Total Laboratory Throughput including commercial, pre-commercial and clinical studies testing
2
CAGR compares Q4 21 to Q4 23
Pacific Edge has Cxbladder coverage in 15 of the 20 new Te
WhatuOra, Health New Zealand, regions, representing >75%
of the country’s population
•Volumes in APAC driven by slower growth in New Zealand
•Australia and Southeast Asia still in business development
•New APAC President recruited in March 2023
▲
-1%
CAGR
2
18

19
19

EVIDENCE, COVERAGE AND GUIDELINES: CHANGE CLINICAL PRACTICE
FOCUS AREAS:
Generate high-quality clinical validation and utility evidence
through clinical studies
Use Clinical Utility evidence to:
Drive the adoption of Cxbladder by clinicians, insurers and
hospitals ahead of guideline inclusion
•Pursue inclusion of Cxbladder in globally-relevant
standards and guidelines of clinical care across the
breadth of patient pathways
•Foster trusted relationships with key opinion
leaders, relevant Urologic centers of excellence,
professional societies and patient advocacy
networks to drive a broader awareness and
demand for Cxbladder
•Develop the scientific and clinical credibility of the
Cxbladder brand
EVIDENCE
COVERAGE AND
GUIDELINES
20

ADDITION OF DNA BIOMARKERS ENHANCES CXBLADDER PERFORMANCE
•New study published in the AUA Journal of Urology
1
:
•Found the addition of DNA biomarkers significantly
enhances the performance of Cxbladder tests for
hematuriaevaluation.
•Demonstrated analytical validity of the enhanced tests
in a genetically diverse population (804 patients: 344
from the US, 460 Singapore)
•CxbDetect
+
is targeted for commercialization as a single
product for hematuriaevaluation in the US and requires:
•New clinical validity and utility evidence:
•DRIVE, microDRIVE, AUSSIE, STRATAand other
planned studies
•Its own coding, coverage and pricing decisions
•No impact is anticipated on existing Triage, Detect and
Monitor revenues, because full commercial launch of Cxb
Detect
+
commences only after reimbursement is established
•Investigating the potential for CxbMonitor
+
for surveillance
of NMIBC
1. Lotan et al ‘Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification’
2.. For definitions, please refer to page 45 of this presentation
Performance
2
SensitivitySpecificityNPVPPVROR
Cxbladdertests enhanced with DNA biomarkers
CxbTriage
+
95%78%99.5%26%73%
CxbDetect
+
97%90%99.7%44%83%
Existing Cxbladder tests
CxbTriage89%63%99%16%59%
CxbDetect74%82%97%25%78%
A Cxb Detect
+
negative patient has a low probability of UC because Cxb Detect
+
combines the
characteristics of high Sensitivity (97%), NPV (99.7%) and Specificity (90%) with a Rule out rate (ROR) of
83%.
A Cxb Detect
+
positive patient conversely has a higher probability of urothelial cancer for the same
reasons. A positive test represents a justification for a full workup for the patient according to guidelines
and assist the adjudication of diagnostic dilemmas such as equivocal cystoscopy or urine cytology.
US and Singapore studies extend Pacific Edge’s first mover advantage in bladder cancer diagnosis
Results of enhanced tests compared to existing tests
1
21

CLINICAL EVIDENCE GENERATION TOWARDS GUIDELINE INCLUSION (1/2)
STUDYAIMLOCATIONSENROLLED
SITES*
STATUS**
STRATASafe Testing of Risk for AsymptomaTIc MicrohematuriA
Demonstrate the clinical utility (CU) of Cxbladder using a prospective, two-arm randomizeddesign to risk-stratify
patients and rule out from cystoscopy
•Establish CU for CxbladderTriage in MH populations to identify patients at low risk of bladder cancer that can
safely avoid cystoscopy
•Retrospective analysis with Cxbladder Detect+ to show equivalent or greater CU in MH populations with the
improved performance characteristics
•CU evidence supports AUA/NCCN guidelines inclusion usingCxbladderTriage and/or CxbladderDetect+ to risk
stratify MH populations
USA
Canada
11 / 13-Enrolment total is 492, including 113 ‘low
risk’ subjects that are the focus of the
study
-Target enrolment: ~600 patients,
including 120 low risk subjects
randomized to test arm
-Last patient in:Q3 2023
-Follow up: until Q3 2024
DRIVE
Detection and RIsk Stratification in VEterans Presenting with Hematuria
Prospectiverecruitmentof patients to a single-arm observational studytodemonstrate the CV of Cxbladder tests in
risk stratifying Veterans presenting with hematuria
•CV evidence for Triage in MH & GH patients supplementing NZ Studies
•Demonstrate CV of Cxbladder Detect+ within a Veterans cohort
•Retrospective analysis with Cxbladder Detect+ to demonstrate CV evidence supportingAUA/NCCN Guidelines
inclusion in MH & GH patients
•Contribute data to pooled-analysis to establish CV for Detect+ in MH patients
VA Sites (USA)10 / 11-Enrolment total is 562
-Target enrolment: ~600 patients
-Last patient in: Q3 2023
-Follow up: until Q2 2025
AUSSIEAustralian Urologic risk Stratification of patientS wIth hEmaturia
Prospectiverecruitmentof patients to a single-arm observationalstudyto demonstrateCV in an Australian
healthcare setting for patients presenting with hematuria
•Demonstrate CVof CxbladderDetect+ with an Australian cohort
•Demonstrate accurate risk stratification of hematuria patients to intensify or de-intensify evaluation
•Contribute data to pooled-analysis to establish CV for Detect+ in MH patients
Australia1 / 1-Enrolment due to start May 2023
*Estimated number of enrolled sites
**All dates are best-case estimates and subject to change
22

STUDYAIMLOCATIONSENROLLED
SITES*
STATUS**
Microhematuria
Pooled-analysis
Pooled-analysisof Cxbladder Detect+ performance from multiple studies involving prospectively recruited
patients from single-arm observational studies including eligible microhematuria patients
•CV of Cxbladder Detect+ withmicrohematuria (MH) patients
•Combines data from DRIVE, AUSSIE and a future MH-focused clinical trial
•CV evidence supports AUA/NCCN guidelines inclusion usingCxbladderDetect+ to risk stratify MH
populations
USA, AusN/A-DRIVE underway, AUSSIE and
microDRIVE projected to start in 2023
microDRIVE
Detection and RIsk Stratification in VEterans Presenting with Microhematuria
•Demonstrate the clinicalvalidity of Cxbladder Detect
+
in detecting urothelial cancer in patients
presenting with microhematuria.
•MicroDRIVE will compare the performance of Detect
+
against the current gold-standard for the
detection of urothelial cancer, diagnostic cystoscopy and pathology.
USA0/1-Projected to start recruitment
Sep/Oct 2023
-Target is 1000 patients and 50
tumour confirmed
-Last patient in: March/April 2024
LOBSTERLOngitudinal Bladder Cancer Study for Tumor REcurRence
Prospectiverecruitmentof patients to a single-arm observational study to evaluate the clinical validityof
CxbM
•To safely risk stratify patients under surveillance for recurrence of UC
•To demonstrate that it is safe to alternate CxbM with cystoscopy for intermediate and high-risk
patients under surveillance for recurrence of UC
•Targeting AUA/NCCN guidelines inclusion for biomarkers as an alternative to cystoscopy in a
surveillance setting
USA (including
some VA sites)
Australia
3 / 10-Three sites are open
-Two due to open in April
-Another 6 are at pre-activation.
-Enrolment is now 63 patients with 98
samples collected to date
-Each site will enroll 100 patients
within 12 months and follow up for
another 12 months
CLINICAL EVIDENCE GENERATION TOWARDS GUIDELINE INCLUSION (2/2)
*Estimated number of enrolled sites
**All dates are best-case estimates and subject to change
23

MEDICAL AFFAIRS: SPEAKING THE LANGUAGE OF CLINICAL OPINION LEADERS
CLINICAL DOSSIER DEVELOPMENT
•Contains all published Cxbladder data; externally reviewed
•Used to engage with guideline committees, private payors, government
payers, value-based clinician groups ex-US distributors, etc.
•Annual NCCN submission of new evidence in August 2023
PODIUMS, PRESENTATIONS, POSTERS AND PUBLICATIONS
•Increase “share of voice” by presenting data on Cxbladder utility in
multiple forums (AUA, SUO, ASCO GU), clinicians, academic institutions
•Publications – support for data generated and published by our users
and KOLs
•Speaker Bureau – trained, external KOLs and senior MSL team members
BUILDING KOL RELATIONSHIPS
•Academics, clinical leads in private practice, guidelines committees and
other influential clinicians
24
VIDEO VIEWS
PUBLISHED
12/2/22
4102

INVESTIGATOR INITIATED TRIALS UNDERWAY AND AIMS SITESPUBLICATIONS
Hematuria Evaluation: Local clinical validity evidence for internal hospital guidelines and budget development62x Conference Abstracts
Surveillance: Local clinical validity evidence for internal hospital guidelines and budget development72x Conference Abstracts
CU of Cxbladder to identify subclinical tumors in white light negative patients, confirmed by blue light1Pending
Risk-based hematuria evaluation of microhematuria patients by Cxbladder1Pending
Prioritization of surveillance patients by Cxbladder monitor for surveillance cystoscopy vs skipping one visit21x Conference Abstract
MEDICAL AFFAIRS: INVESTIGATOR INITIATED TRIALS AND REGISTRIES
SUPPLEMENTING OUR EVIDENCE GENERATION PROGRAM
INVESTIGATOR INITIATED TRIALs (IITs)
•Proposed by investigators and supported by Pacific Edge to provide
clinical utility evidence at modest scale for medical communications
•Promote familiarity and confidence with Cxbladder, the interpreting the
test result and how Cxbladder can be used to manage patients
•Supports local data development for market access
PACIFIC EDGE’S CXBLADDER REGISTRY
•Multi-site, real-world evidence clinical trial, capturing wide-ranging
patient data, including follow up and outcomes data
•Assists independent investigators with study design and provides a data
repository to support coverage and guideline decisions
Left to right:
Royal Prince Alfred Hospital (Sydney)
, UT Southwestern (Dallas), Canberra Hospital (ACT)
25

MARKET ACCESS: EXPANDING COVERAGE
WORKING WITH PUBLIC AND PRIVATE HEALTHCARE PAYORS GLOBALLY
MEDICARE STRATEGY
•Triage joins Monitor & Detect on LCA58917 with coverage at
US$760/test*
•Reconsideration request with Novitas for all Cxbladder tests
•Working towards PLA-coding, coverage and pricing for Detect
+

•Active program of appeals and prior-authorization workflows to
increase payment rates from Medicare Advantage Plans
PRIVATE PAYOR STRATEGY
•Localized, demand-based approach focused on establishing medical
policy, then contracting with individual private payors
•Health Economics –documenting the economic benefits to healthcare
payors of adopting Cxbladder as a standard of care
EX-US DISTRIBUTORS SUPPORTED BY PEDUSA
•ProGenetics(Israel) distribution agreement signed
•Other geographies under consideration on a case-by-case basis
26
Distribution of Current
U.S. Customers
Pacific Edge Diagnostics
USA, Hershey,
Pennsylvania
*The coverage position of Cxbladder may change. Proposed LCD (DL39365 – Genetic Testing for Oncology) issued in
July 2022, must be finalized or withdrawn within 12 months of proposal

RESEARCH AND INNOVATION:
UNDERSTANDING THE ENTIRE COMMERCIALISATION PATHWAY
INTELLECTUAL
PROPERTY
TECHNOLOGYPRODUCT
COMMERCIALISATION
FOCUS AREAS:
1.Evaluate ‘product concepts’ to address unmet clinical needs through market research and scientific/clinical advisory boards
2.Evaluate cutting-edge technologies to meet the market requirements of desired product concepts
3.Continue to build a patent portfolio for novel clinical applications of cutting-edge molecular technologies
4.Turn patented technology into clinically-validated molecular diagnostic tools that address an unmet clinical need
RESEARCH &
INNOVATION
27

RESEARCH AND INNOVATION
DRIVING IP TO TECHNOLOGY
•Te c h n o l o g y t ra n s fe r o f D e t e c t
+
from R&D to PEDNZ and PEDUSA clinical labs
•Evaluate ‘product concepts’ to address unmet clinical needs
•Simplify & productize Cxbladder workflows for performance excellence
•Adding DNA SNP markers to Cxbladder Monitor to evaluate the possibility
of enhanced performance characteristics
•MONSTER: identifying additional markers of disease in surveillance patients
•Rationale: Gene expression markers perform poorly within 6 months
of surgical intervention (TURBT) and after administration of
therapeutics
•Opportunities within 6 months of intervention:
•Minimum Residual Disease(MRD)
•Therapeutic Response Monitoring(TRM)
MONSTER
MONitoringStudy of post-Treatment Effectiveness for Residual Disease
Single-arm, observational study to validate the performance characteristics of Cxbladder
against white light cystoscopy during surveillance of UC
•Christchurch-based sample collection to measure residual disease
•To u n d e rs t a n d t h e p o t e n t i a l o f C x b l a d d e r i n i d e n t i f y i n g t h e ra p e u t i c re s p o n s e fo r s u rg i c a l
and non-surgicaltreatments of bladder cancer.
-Protocol under development,
consulting with medical experts
and pharma partners to guide
the best study design
Christchurch Hospital
28

FINANCIAL RESULTS OVERVIEW
29

$1,425
$2,033
$2,285
$3,326
$5,378
$8,707
$1,975
$1,784
$2,085
$4,375
$6,067
$10,909
$0
$5,000
$10,000
$15,000
$20,000
$25,000
FY 18FY 19FY 20FY 21FY 22FY 23
$(000)
1H2H
US TEST COMMERCIAL TEST VOLUME GROWTH DRIVING FY 23 REVENUES
$11,445
$7,701
$4,370
$3,817
$3,400
FY 23
Pacific Edge Operating Revenue
Regional Revenue Split
FY 22
▲
71%
USA APAC
$19,616
4%
96%
7%
93%
30

FINANCIAL PERIOD (March Year)FY 23FY 22FY 21
FY 23 vs
FY 22
$000$000$000
△
%
Operating revenue$19,616$11,445$7,70171%
To t a l re v e n u e$26,124$13,878$10,43988%
Operating expenses$53,089$33,666$24,66258%
Total comprehensive loss-$27,064-$19,674-$14,17738%
Cash receipts from customers$18,468$10,942$6,74769%
Net operating cash outflow-$25,575-$17,552-$13,57046%
Net cash, cash equivalents and
short term deposits
$77,791$105,412$23,129-26%
A STRONG BALANCE SHEET SUPPORTING GROWTH INVESTMENT
•Operating revenue growth of 71% driven by
growth in US testing volumes
•Operating expenses increased 58% due primarily
to investment for growth in sales and marketing
and research (~73%) and volume increase of
Cxbladder (~15%)
•Cash and cash equivalents of $77.8m down
$15.7m on $93.5m in 1H 23
1
and $27.6m on FY 22
•Removing the impact of changes in foreign
exchange between FY 22 and FY 23:
•Operating revenue grew 55%
•Operating expenses increased 47%
•To t a l co m p re h e n s i v e l o s s i n c re a s e d 3 1 %
1
30 September 2022
31

FINANCIAL PERIOD (March Year)FY 23FY 22FY 21
FY 23 vs
FY 22
$000$000$000
△
%
Laboratory operations $9,349$6,498$5,46644%
Research$8,484$5,135$4,58465%
Sales and marketing $25,123$14,277$9,20276%
General and administration$10,133$7,756$5,41031%
Total operating expenses$53,089$33,666$24,66258%
OPERATING EXPENSES RISE WITH INVESTMENT AND VOLUME GROWTH
•Investment in people accounted for ~52% of the
expense growth, e.g. headcount, salary increases and
recruitment costs
•Sales and Marketing investment accounted for ~56%
of the expense growth, including the majority of
Medical Affairs expense
•Laboratory operations expenses increased ~ 44%
following higher throughput and freight costs
•Research costs have increased ~ 65% as increased
clinical evidence generation focuses on guideline
inclusion
32

ENVIRONMENTAL SOCIAL AND GOVERNANCE STRATEGY
33

34
ESG: PACIFIC EDGE IS FOUNDED ON IMPROVING SOCIAL OUTCOMES
GOVERNANCE
•Integrating oversight of Environmental, Social and Governance (ESG)
matters, including carbon reporting, into the Audit and Risk Committee
Charter
AOTEAROA NEW ZEALAND CLIMATE STANDARDS
•Measured carbon emissions (Scope 1, 2, 3) in FY 23 and positioned to
provide base year data in FY 24
•Working closely with To i t ūEnvirocare to accurately audit and measure
our greenhouse gas emissions, as we work towards achieving
certification in respect of FY 24
•Developing strategies and policies and evolving our risk management
framework to meet our reporting requirements.
ATTRACTING AND RETAINING TALENT AT PACIFIC EDGE
•We actively promote diversity, inclusion, engagement and fair
remuneration
Pacific Edge is delivering actionable informationthat can contribute to a clinically meaningful improvements in cancer
treatment, improving lives, improving healthcare equity across populations and healthcare outcomes for patients
PROMOTING HEALTH CARE EQUITY
Following the introduction of Cxbladder into primary care in Te
WhatuOra Canterbury, referrals to urologists were safely reduced,
urological waiting lists fell by 25%
1
1. Davidson, Peter; Presentation to Urofair, 2022, time to first specialist assessment.

OUTLOOK: FOCUSED ON FY24 EXECUTION
•Building on steady growth in FY23, investing prudently to improve
effectiveness metrics (e.g. throughput/headcount, throughput/clinician)
•HEADWINDS:
•No response by Novitas to comments submitted by Pacific Edge or
other companies on proposed LCD
•CATALYSTS:
•Novitas publishes a final LCD retaining coverage under LCA58917
•Kaiser EMR integration “go live” in Southern California
•Sales force maturity & territory stability improve effectiveness
•TeWhatuOra national contract
•New clinician-generated CU evidence as studies completed
•We have world-leading technology, a strong balance sheet and we are
building momentum in the US and establishing footholds in new markets
35

QUESTIONS
36

APPENDIX
37

Mission
To help improve people’s lives and
patient outcomes by providing leading
solutions for the early detection and
management of cancer.
Vision
A world where the early diagnosis and
better treatment of cancer is within
reach of everyone.
“Nobody should die of cancer”
38

PACIFIC EDGE: RESEARCH, INNOVATION, COMMERCIALIZATION
2001
2001
Pacific Edge
established
2007
2007
Commercial
pivot to
focus on
urothelial
cancer
diagnostics
2008
Holyoake et al: Urine-
based RNA detection
of urothelial cancer.
Clin Cancer Res
2008
2011
2010
Pacific Edge
Diagnostics
New Zealand
(PEDNZ)
established
2012
2012
O’Sullivan et al:
Cxbladder Detect
performance
validation.
Journal of Urology
Dec 2012
Launch of Pacific Edge
Diagnostics USAand
Cxb Detect
2013
Mar 2013
PEDUSA receives
CLIA
accreditation
May 2013
First commercial
sale (Cxb Detect)
for PEDNZ
Mar 2013
First commercial
sale (Cxb Detect)
for PEDUSA
2014
Dec 2014
Launch of Cxbladder
Triage
2015
Mar 2015
Kavalieris et al:
Cxb Triage
performance
validation. BMC
Urology
Dec 2015
Launch of
Cxbladder
Monitor
2016
Nov 2016
Clinical trials
commence in
Singapore
2018
Feb 2018
Cxb Triage
adopted into
Canterbury
Community Health
Pathways with
primary care
referral
2019
Aug 2019
Konety et al: Clinical
Utility of Cxb Detect
in adjudicating
atypical cytology and
equivocal
cystoscopy.European
Urology
2020
Apr 2020
Patient in-home
sampling initiated in
the US
Jun 2020
Kaiser Permanente,
approves commercial
use of Cxbladder
Jul 2020
CMS confirms
reimbursement of
Cxbladderat
$760/test
2021
Aug 2021
Cxbladder reaches
70% public
healthcare
coverage in NZ
Oct 2021
PEB raises
$103.5m
(~US$72.5m)
Dec 2021
First commercial
sale of Cxbladder
in Australia
2003
Listed on
the NZX
Cxbladder
TRIAGE
Cxbladder
DETECT
Cxbladder
MONITOR
2022
Dec2022
Lotan et al:
Enhanced
Cxbladder
Tests Deliver
Improved
Performance.
Journal of
Urology
39

GLOBAL GUIDELINES PIVOTAL TO THE WIDESPREAD ADOPTION OF CXBLADDER
Recognition in national guidelines deepens and accelerates commercial use of Cxbladder tests and entrenches
coverage by nationally relevant healthcare institutions.
•Most influential and largest
urologicalassociation in the world
•U.S. based -23,000 members worldwide.
•Standards of care relevant to Cxbladder:
•Hematuriaand micro-hematuria
management
•Non-muscle invasive bladder
cancer (NMIBC). (Standard makes
an allowance for the use of
biomarkers in surveillance)
•Guidelines reviewed as new evidence
emerges
•Pacific Edge can influence this process by
publishing new clinical evidence
www.auanet.org
•Leading urologic authority in Europe
•Netherlands-based, 18,000 members
•Standards relevant to Cxbladder
•Non-muscle invasive bladder
cancer (NMIBC)
•Guidelines loosely followed in New
Zealand, Australia and Singapore,
but localised at a national and
regional level
•Guidelines recently reviewed with
favourable biomarkerlanguage and are
updated regularly
www.uroweb.org
•US-based not-for-profit alliance of 32
leading US cancer centres
•Bladder cancer standard suggests
biomarkers may be considered during
surveillance of high-risk non-muscle-
invasive bladder cancer
•Guidelines reviewed annually. PEB will
resubmit in every year where there is new
peer-reviewed evidence for Cxbladder
www.nccn.org
40

SUMMARY OF CLINICAL EVIDENCE
StudyPop.TypeSensitivity (Sn)NPVSpecificity (Sp)Comment
Detect+
AVLotan et al., 2022MH + GH*97%99.7%90%Pooled data from US and Singapore cohorts (n=804)
CV
DRIVE (unpublished) (1)MH + GH*Study in progress
AUSSIE (unpublished) (4)MH + GH*Study to start this year
microDRIVE (unpublished)
(5)
MH*Study to start this year
Triage
AVKavalieriset al., 2015MH + GH*95.10%98.50%45%Sn, Sp, NPV values when test-negative rate is 40%
CV
Davidson et al., 2019MH + GH*95.5% (1)98.6% (1)34.3%GH only: Sn (95.1%), NPV(98%), Sp(32.8%); MH only: Sn (100%), NPV (100%), Sp(42.6%)
Konetyet al., 2019(2)100%
Cxbladder (3) correctly adjudicated all UC confirmed patients (n=26) with atypical urine cytology
results (n=153, 4)
Lotan et al., 2022MH + GH*89%99%63%Pooled data from US and Singapore cohorts (n=804)
CU
Davidson et al., 2020MH + GH*89.4% (5)98.9% (5)59% (5)
39% of patients testing negative for Cxb Triage & imaging did not get cystoscopy & were
managed at primary care (6)
STRATA (unpublished) (7)MH + GH*Study in progress
Detect
AVO'Sullivan et al., 2012GH*81.8%97%85.1%CxbDetect detected 97% of HG tumors& 100% of Stage 1 or greater tumors.
CV
Lotan et al., 2022MH + GH*74%97%82%Pooled data from US and Singapore cohorts (n=804)
DRIVE (unpublished) (1)MH + GH*Study in progress
Monitor
AVKavalieriset al., 2017(1)88% (2)97% (2)N/A(3)
CVKonetyet al., 2019(4)100%
Cxbladder(5) correctly adjudicated all UC confirmed patients (n=26) with atypical urine cytology
results (n=153, 6)
CUKoya et al., 2020(7)
Integration of CxbMonitor into the surveillance schedule reduced annual cystoscopies (39%)
(8,9)
* Referred
MH: Microhematuria, GH: Gross Hematuria. For definitions of Sensitivity, NPV and Specificity please see the glossary on page 33 of this presentation
41

FOOTNOTES FOR CLINICAL EVIDENCE SUMMARY
Footnotes
Detect+
1Observational study to validate performance characteristics and clinical utility of Cxbladder tests (CxbTriage, CxbDetect, CxbDetect
+
).
2Observational study to validate performance characteristics of CxbDetect
+
in patients with UC of the upper tract.
3Patients with suspected upper tract UC (UTUC) or surveillance patients with a history of UTUC.
4Observational study to validate performance characteristics and clinical utility of Cxbladder tests (CxbTriage, CxbDetect, CxbDetect
+
).
5Observational study to validate performance characteristics of CxbDetect
+
in microhematuria(MH) patients.
Triage
1CxbTriage performance; CxbTriage & imaging combined performance had a Snof 97.7% & NPVof 99.8%.
2Patients included hematuriaevaluation (n=436) or surveillance previously diagnosed with UC (n=416) with both Cxbladder& urine cytology results.
3Cxbladder includes Cxbladder Triage & Cxbladder Monitor.
4This included n=70 for patients with hematuria& n=83 for patients with previously diagnosed UC and overall test negative rate of 30.7%.
5CxbTriage performance; CxbTriage & imaging combined performance had a Snof 98.1%,NPV of 99.9% & Spof 98.4%.
6CxbTriage negative rate was 53%; Follow-up period of 21-months showed no missed cancers, demonstrating safety.
7The intent of STRATA is to show that it is safe to risk stratify low risk microhematuriapatients and not undertake cystoscopy.
Detect
1
Observational study to validate performance characteristics and clinical utility of Cxbladder tests (CxbTriage, CxbDetect, CxbDetect
+
).
Monitor
1Surveillance patients previously diagnosed with primary or recurrent UC.
2CxbMonitor performance characteristics on surveillance patients diagnosed with primary UC; CxbMonitor had a Snof 93% and NPV of 94% on patients with recurrent UC.
3Using Kavalieriset al., (2017) data set, Lotan et al., (2017) compared relative performance of CxbMonitor against NMP22 ELISA, NMP22 BladderChekand urine cytology.
4Patients included hematuriaevaluation (n=436) or previously diagnosed UC (n=416) with both Cxbladder& urine cytology results.
5Cxbladderincludes CxbladderTriage & CxbladderMonitor.
6This included n=70 for patients with hematuria& n=83 for patients with previously diagnosed UC; test negative rate of 30.7%.
7All patients were being evaluated for recurrence of UC (n=309 providing 443 samples).
8CxbMonitor identified all seven confirmed recurrence events idnetifiedon the first cystoscopy.
9Patients returning negative CxbMonitor results (n=235) had no pathology-confirmed recurrence at 1st cystoscopy
42

REFERENCES SUMMARY OF CLINICAL EVIDENCE
References
Detect+
Lotan et al., (2022). Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of CxbladderTests and Improves Patient Risk Stratification.The Journal of Urology, 10-
1097.
Triage
Davidson et al., (2019). Inclusion of a molecular marker of bladder cancer in a clinical pathway for investigation of haematuria may reduce the need for cystoscopy.NZ Med J,132(1497), 55-64.
Davidson et al., (2020). Assessment of a clinical pathway for investigation of haematuria that reduces the need for cystoscopy.The New Zealand Medical Journal (Online),133(1527), 71-82.
Kavalieriset al., (2015). A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria
who have a low probability of urothelial carcinoma.BMC urology,15(1), 1-12.
Konety et al., (2019). Evaluation of cxbladder and adjudication of atypical cytology and equivocal cystoscopy.European urology,76(2), 238-243.
Lotan et al., (2022). Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of CxbladderTests and Improves Patient Risk Stratification.The Journal of Urology, 10-1097.
Detect
Lotan et al., (2022). Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification.The Journal of Urology, 10-
1097.
O'Sullivan et al., (2012). A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria.The Journal of urology,188(3), 741-747.
Monitor
Kavalieris et al., (2017). Performance characteristics of a multigene urine biomarker test for monitoring for recurrent urothelial carcinoma in a multicenter study.The Journal of
Urology,197(6), 1419-1426.
Konety et al., (2019). Evaluation of cxbladder and adjudication of atypical cytology and equivocal cystoscopy.European urology,76(2), 238-243.
Koya et al., (2020). An evaluation of the real world use and clinical utility of the Cxbladder Monitor assay in the follow-up ofpatients previously treated for bladder cancer.BMC
urology,20(1), 1-9.
Lotan et al., (2017). Clinical comparison of noninvasiveurine tests for ruling out recurrent urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 35 (8), 531-539.
43

INDEPENDENT DIRECTORS
SARAH PARK
ANATOLE MASFEN
BRYAN WILLIAMS
ANNA STOVE
MARK GREEN
TONY BARCLAY
CHRIS GALLAHER
Chairman
Chris has held senior positions in
both CEO and CFO roles with large
international companies and was a
partner in Arthur Young, Chartered
Accountants. Prior to retiring from
full time corporate life, he was CFO
of Fulton Hogan, a large New
Zealand civil contractor.
DR PETER MEINTJES
Chief Executive Officer
Peter is a molecular diagnostics and
genomics leader focused on
nascent market development of
disruptive innovations to drive
commercial success. Prior to joining
Pacific Edge, he was based in
Boston in a succession of diagnostic
leadership roles. Most recently he
was the Chief Commercial Officer
at Eurofins Transplant Genomics
and before that CEO at Omixon.
SENIOR LEADERSHIP TEAM
GRANT GIBSON DAVID LEVISON DR TAMER ABOUSHWAREB
Chief Financial Officer President Pacific Edge USA Chief Medical Officer
GLEN COSTIN DARELL MORGAN DR JUSTIN HARVEY
President Asia Pacific Chief Operating Officer Chief Technology Officer
ANDY MCINTOSH
Chief Digital Officer
PACIFIC EDGE BOARD AND MANAGEMENT
44

GLOSSARY
•Sensitivity - the frequency with which a test correctly identifies patients with a disease.
•Specificity - the frequency with which a test correctly identifies patients without a disease.
•Negative Predictive Value (NPV) - the percentage of negative tests being true negatives (by standard of care).
•Positive Predictive Value (PPV) - the percentage of positive tests being true positives (by standard of care).
•Rule-out Rate (ROR) - the percentage of tests that return a negative result.
•Evidence definitions:
•Analytical validity: Develop a test that is repeatable in the lab for a given indication and population.
•Clinical validity: Make sure the test works in the same way on an independent eligible population for the given indication.
•Clinical utility: Put the test in the hands of a physician to establish that it can usefully change patient management within the
context of care for the defined population and indication.
45

FOR MORE INFORMATION:
Dr. Peter Meintjes
Chief Executive Officer
email: peter.meintjes@pelnz.com
Grant Gibson
Chief Financial Officer
email: grant.gibson@pelnz.com
Pacific Edge
87 St David Street, PO Box 56, Dunedin, New Zealand
P +64 3 479 5800 F +64 3 479 5801
email: investors@pacificedge.co.nz
www.pacificedgedx.com
46

---

23
CONSOLIDATED
FINANCIAL
STATEMENTS
FOR THE YEAR ENDED
31 MARCH 2023

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
2
Consolidated Financial Information
Consolidated Statement of Comprehensive Income 3
Consolidated Statement of Changes in Equity 4
Consolidated Balance Sheet 5
Consolidated Statement of Cash Flows 6
Notes to the Consolidated Financial Statements 7
Independent Auditor’s Report 36
Company Directory 41

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
3
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
For the year ended 31 March 2023
Note: These Financial Statements are to be read in conjunction with the Notes to the Financial Statements
Notes
2023
($000)
2022
($000)
REVENUE
Operating Revenue 5 19,616 11,445
Total Operating Revenue 19,616 11,445
Other Income5 1,417 1,691
Interest Income9 2,761 549
Foreign Exchange Gain 2,330 193
Total Revenue and Other Income 26,124 13,878
OPERATING EXPENSES
Laboratory Operations 9,349 6,498
Research6 8,484 5,135
Sales and Marketing 25,123 14,277
General and Administration7 10,133 7,756
Total Operating Expenses 53,089 33,666
NET LOSS BEFORE TAX (26,965) (19,788)
Income Tax Expense16- -
LOSS FOR THE YEAR AFTER TAX (26,965) (19,788)
Items that may be reclassified to profit or loss:
Translation of Foreign Operations (99) 114
TOTAL COMPREHENSIVE LOSS attributable to
equity holders of the Company
(27,064) (19,674)
Earnings per share for loss attributable to the equity
holders of the Company during the year
Basic and Diluted Earnings per share3 (0.033) (0.026)

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
4
Share
Capital
Accumulated
Losses
Share
Based
Payments
Reserve
Foreign
Currency
Translation
Reserve
Total
Equity
Notes($000)($000)($000)($000)($000)
Balance as at 31 March 2021 190,305 (170,061) 4,038 827 25,109
Loss after tax- (19,788)- - (19,788)
Other Comprehensive Income- - - 114 114
TOTAL COMPREHENSIVE LOSS
attributable to equity holders of the
Company
- (19,788)- 114 (19,674)
Transactions with owners in their
capacity as owners:
Issue of Share Capital18 99,622 - - - 99,622
Share Based Payments- Employee
Remuneration
8 172 - - - 172
Share Based Payment- Employee
Share Options
8 4,040 - (893)- 3,147
Balance as at 31 March 2022 294,139 (189,849) 3,145 941 108,376
Balance as at 31 March 2022 294,139 (189,849) 3,145 941 108,376
Loss after tax- (26,965)- - (26,965)
Other Comprehensive Income- - - (99) (99)
TOTAL COMPREHENSIVE LOSS
attributable to equity holders of the
Company
- (26,965)- (99) (27,064)
Transactions with owners in their
capacity as owners:
Issue of Share Capital18 (4)- - - (4)
Share Based Payments- Employee
Remuneration
8 182 - - - 182
Share Based Payment- Employee
Share Options
8- - 1,273 - 1,273
Balance as at 31 March 2023294,317 (216,814) 4,418 842 82,763
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
For the year ended 31 March 2023
Note: These Financial Statements are to be read in conjunction with the Notes to the Financial Statements

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
5
CONSOLIDATED BALANCE SHEET
As at 31 March 2023
Notes
2023
($000)
2022
($000)
CURRENT ASSETS
Cash and Cash Equivalents9 33,229 35,412
Short Term Deposits9 44,562 70,000
Receivables10 5,493 4,012
Inventory11 1,287 1,007
Other Assets12 1,400 1,183
Total Current Assets 85,971 111,614
NON-CURRENT ASSETS
Property, Plant and Equipment13 2,768 1,404
Right of Use Assets23 1,143 1,830
Intangible Assets14 1,031 434
Total Non-Current Assets 4,942 3,668
TOTAL ASSETS 90,913 115,282
CURRENT LIABILITIES
Payables and Accruals17 6,928 4,983
Lease Liabilities23 811 1,072
Total Current Liabilities 7,739 6,055
NON-CURRENT LIABILITIES
Lease Liabilities23 411 851
Total Non-Current Liabilities 411 851
TOTAL LIABILITIES 8,150 6,906
NET ASSETS 82,763 108,376
Represented by:
EQUITY
Share Capital18 294,317 294,139
Accumulated Losses (216,814) (189,849)
Share Based Payments Reserve 4,418 3,145
Foreign Translation Reserve 842 941
TOTAL EQUITY 82,763 108,376
FURTHER INFORMATION
Net Tangible Assets per share ($) 0.101 0.133
For and on behalf of the Board of Directors dated the 24th day of May 2023:
Director Director
Note: These Financial Statements are to be read in conjunction with the Notes to the Financial Statements

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
6
CONSOLIDATED STATEMENT OF CASH FLOWS
For the year ended 31 March 2023
Note: These Financial Statements are to be read in conjunction with the Notes to the Financial Statements
Notes
2023
($000)
2022
($000)
CASH FLOWS TO OPERATING ACTIVITIES
Cash was provided from:
Receipts from Customers 18,468 10,942
Receipts from Grant Providers 1,066 1,413
Interest Received 2,716 365
22,250 12,720
Cash was disbursed to:
Payments to Suppliers and Employees 47,869 30,198
Net GST (inflow) cash outflow (44) 74
47,825 30,272
Net Cash Flows To Operating Activities20 (25,575) (17,552)
CASH FLOWS FROM (TO) INVESTING ACTIVITIES:
Cash was provided from:
Proceeds from Short Term Deposits 143,490 51,837
143,490 51,837
Cash was disbursed to:
Purchase of Short Term Deposits 118,107 102,837
Capital Expenditure on Plant and Equipment 1,870 713
Capital Expenditure on Intangible Assets 1,039 413
121,016 103,963
Net Cash Flows From (To) Investing Activities 22,474 (52,126)
CASH FLOWS (TO) FROM FINANCING ACTIVITIES:
Cash was received from:
Ordinary Shares Issued18 (4) 103,488
Exercising of Share Options- 2,306
(4) 105,794
Cash was disbursed to:
Repayment of Leases- Principal23 1,195 1,147
Repayment of Leases- Interest23 83 126
Issue Expenses18- 3,865
1,278 5,138
Net Cash Flows (To) From Financing Activities (1,282) 100,656
Net (Decrease) increase in Cash Held (4,383) 30,978
Add Opening Cash Brought Forward 35,412 4,129
Effect of exchange rate changes on net cash 2,200 305
Ending Cash Carried Forward9 33,229 35,412

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
7
Notes to the Consolidated Financial Statements
For the year ended 31 March 2023
1. ACCOUNTING POLICIES
SUMMARY OF ACCOUNTING POLICIES
Reporting Entity
The consolidated financial statements (hereafter referred to as the ‘financial statements’) presented for the year
ended 31 March 2023 are for Pacific Edge Limited (the ‘Company’) and its subsidiaries (collectively referred to as
the ‘Group’). The Group’s purpose is to research, develop and commercialise new diagnostic and prognostic tools
for the early detection and management of cancers.
Pacific Edge Limited is registered in New Zealand under the Companies Act 1993 and is a Financial Markets
Conduct (FMC) reporting entity under Part 7 of the Financial Markets Conduct Act 2013. The financial statements
of the Group have been prepared in accordance with the requirements of the Financial Markets Conduct Act 2013
and the NZX Listing Rules. The financial statements presented are those of the Group, consisting of the Parent
entity, Pacific Edge Limited and its subsidiaries. The Company is dual listed, with its primary listing of ordinary
shares quoted in New Zealand on the NZX Main Board, and a secondary listing in Australia as a Foreign Exempt
Entity on the ASX.
These financial statements have been approved for issue by the Board of Directors on the 24th May 2023.
Basis of Preparation
These financial statements of the Group have been prepared in accordance with Generally Accepted Accounting
Practice in New Zealand (NZ GAAP). The Group is a for-profit entity for the purposes of complying with NZ GAAP.
The financial statements comply with New Zealand equivalents to International Financial Reporting Standards (NZ
IFRS), other New Zealand accounting standards and authoritative notices that are applicable to entities that apply
NZ IFRS. The financial statements also comply with International Financial Reporting Standards.
The financial statements are presented in New Zealand Dollars, which is the Company’s functional currency and
Group’s presentation currency, and all values are rounded to the nearest thousand dollars ($000). The accounting
principles recognised as appropriate for the measurement and reporting of earnings, cash flows and financial
position on a historical cost basis have been used.
The Consolidated Statement of Comprehensive Income and Consolidated Statement of Cash Flows have been
prepared so that all components are stated net of GST. All items in the Consolidated Balance Sheet are stated net
of GST, with the exception of receivables and payables.
Management of Capital
The capital structure of the Group consists of equity raised by the issue of ordinary shares in the Company. The
Company’s objectives when managing capital are to safeguard the Company’s ability to continue as a going
concern in order to provide returns for shareholders, provide benefit for other stakeholders and to maintain an
optimal capital structure to support the development of its business. The Company meets these objectives through
closely managing revenue and expenditure, and where required issues new shares.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
8
Notes to the Consolidated Financial Statements
For the year ended 31 March 2023
Basis of Consolidation
The following entities and the basis of their inclusion for consolidation in these Financial Statements are as follows:
Name of Subsidiary
Place of
Incorporation
(or registration)
& Operation
Principal Activity
Ownership Interests
& Voting Rights
31 March
2023
%
31 March
2022
%
Pacific Edge Diagnostics New Zealand
Limited
New Zealand
Commercial Sales and
Diagnostic Laboratory
Operation
100100
Pacific Edge (Australia) Pty LimitedAustralia
Commercial Sales and
Biotechnology Research
& Development
100100
Pacific Edge Diagnostics USA LimitedUSA
Commercial Sales and
Diagnostic Laboratory
Operation
100100
Pacific Edge Diagnostics Singapore
Pte Limited
Singapore
Commercial Sales and
Biotechnology Research
& Development
100100
Pacific Edge Analytical Services
Limited
New ZealandDormant Company100100
The financial statements incorporate the assets, liabilities and results of all subsidiaries of Pacific Edge Limited as at
31 March 2023 and for the year then ended. All subsidiaries have the same balance date as the Company of 31 March.
Pacific Edge Limited consolidates all entities over which Pacific Edge Limited has control. Control is achieved when
the Group:
• has power to direct the activities of the entity;
• is exposed, or has rights, to variable returns from involvement with the entity; and
• has the ability to use its power to affect its returns.
Subsidiaries which form part of the Group are consolidated from the date on which control is transferred to the
Group. They are de-consolidated from the date that control ceases.
The acquisition method of accounting is used to account for business combinations by the Group. The consideration
transferred for the acquisition of a subsidiary is the fair value of the assets transferred, the liabilities incurred and the
equity interest issued by the Group.
The consideration transferred includes the fair value of any asset or liability resulting from a contingent consideration
arrangement. Acquisition-related costs are expensed as incurred. Identifiable assets acquired and liabilities and
contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition
date. On an acquisition-by-acquisition basis, the Group recognises any non-controlling interest in the acquiree either
at fair value or at the non-controlling interest’s proportionate share of the acquiree’s net assets. Inter-company
transactions, balances and unrealised gains on transactions between Group companies are eliminated. Unrealised
losses are also eliminated. Accounting policies of subsidiaries have been changed where necessary to ensure
consistency with the policies adopted by the Group.
Critical Accounting Estimates and Assumptions
In preparing these financial statements, the Group made estimates and assumptions concerning the future.
These estimates and assumptions may differ from the subsequent actual results. Estimates and assumptions are
continually evaluated and are based on historical experience and other factors including expectations or future
events that are believed to be reasonable under the circumstances.
There has been a change in a Critical Accounting Estimate for commercial test revenue recognised in the US, which
has resulted in Operating Revenue increasing by $418,000 for the reporting period ended 31 March 2023. This is
detailed in Note 5.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
9
Notes to the Consolidated Financial Statements
For the year ended 31 March 2023
The Group has performed an initial assessment of potential climate related risks and considered the location of
laboratories and other key operations in each region that it operates in and concluded that there is no material
impact on the current financial statements.
All other significant accounting policies have been applied on a basis consistent with those used in the audited
financial statements of Pacific Edge Limited for the year ended 31 March 2022.
2. NEW STANDARDS
New and Amended Standards Adopted by the Group
There are no new standards or interpretations material to the Group to be applied during the year.
New Standards and Interpretations Not Yet Adopted by the Group
Certain new accounting standards and interpretations have been published that are not mandatory for 31 March
2023 reporting periods and have not been early adopted by the Group. These standards are not expected to have
a material impact on the entity in the current or future reporting periods and on foreseeable future transactions.
3. EARNINGS PER SHARE
(a) Basic
Basic earnings per share is calculated by dividing the profit (or loss) attributable to equity holders of the Company
by the weighted average number of ordinary shares on issue during the year excluding ordinary shares purchased
by the Company (Note 18).
GROUP
2023
($000)
2022
($000)
Loss attributable to equity holders of the Company (26,965) (19,788)
Weighted average number of ordinary shares on issue810,226 767,924
Earnings per share (0.033) (0.026)
(b) Diluted
Diluted earnings per share is calculated by adjusting the weighted average number of shares outstanding to
assume conversion of all dilutive potential ordinary shares. The Group’s dilutive potential ordinary shares are in the
form of share options. As the Group made a loss during the current year and losses cannot be diluted, basic and
diluted earnings per share are the same.
4. LABORATORY THROUGHPUT AND COMMERCIAL TESTS –
NON-GAAP REPORTING
Laboratory Throughput is a key metric for the Group: Laboratory Throughput provides evidence of the usage of
Cxbladder products globally and the rates of adoption between different customer segments. The inclusion of this
non-GAAP reporting is considered helpful to readers of these consolidated financial statements, as it allows readers
to compare the current period to prior periods and assess usage trends on a consistent basis. Total laboratory
throughput includes commercial tests, which are invoiced to customers (including tests for patients covered by
the US government’s medical program through the Centers for Medicare and Medicaid Services (CMS)), and
tests which are not considered to be commercial as these tests relate to Research Tests or other non-chargeable
activities.
Commercial Test numbers are also a key metric for the Group: Commercial Tests are those tests for which the
Company is actively seeking reimbursement and cash receipts, and tests performed at no charge in order to gain
new customers. The inclusion of this non-GAAP reporting is considered helpful to readers of these consolidated
financial statements as it allows readers to compare the current period to prior periods and assess trends on a
consistent basis.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
10
Notes to the Consolidated Financial Statements
For the year ended 31 March 2023
Laboratory Throughput and Commercial Tests per financial year are shown below.
FY23FY22
Total Laboratory Throughput (tests) 31,565 23,086
Change in Total Laboratory Throughput (%) 37%46%
Change in Throughput from previous year (tests) 8,479 7,272
Total Commercial Tests (tests) 26,691 19,196
Change in Commercial Tests from previous year (%)39%48%
Change in Commercial Tests from previous year (tests)7, 4 9 56,220
Commercial Tests as a percentage of Total Laboratory
Throughput (%)
85%83%
5. REVENUE
Background information on US customers and the payment process
A physician orders a Cxbladder test when a patient presents to their clinic with symptoms that indicate the
possibility of bladder cancer. The most common and significant symptom is haematuria or blood in their urine.
A urine sample is collected from the patient and sent in the Cxbladder Urine Sampling System to the Group’s
laboratory in the US or in New Zealand. The Group receives and processes the urine sample and returns the results
of the test back to the ordering physician. The individual patient is the Group’s customer, however typically in the
US market, the patient’s insurer may pay the Group for some or all of the cost of the test.
When a physician orders a Cxbladder test, the Group has an obligation to perform the test and report the results to
the ordering physician irrespective of the patient’s insurance contract. A patient may have private insurance cover,
be covered by the US government’s medical program through CMS, self cover or have no insurance cover.
Once the Cxbladder test has been completed, all information required for insurance purposes is sent to the Group’s
billing and reimbursement agent to begin the process to collect reimbursement from any applicable insurance
company/ies for the Cxbladder test performed.
For patients with private insurance cover, the relevant patient and test order information will be sent to their
insurance provider. When the Group does not have an individual agreement with that insurance provider to pay
for Cxbladder tests (“out of network”), the insurance provider will assess that individual patient’s test for medical
necessity and the level of insurance cover (if any) available to cover the cost of the test. This process of assessment
can take many months to work through before the Group receives payments (if any) from the insurance company.
The Group does have agreements with some insurance providers but these currently cover a small proportion of
the Group’s customers.
For patients covered by CMS, invoices are sent to CMS. Prior to 3 July 2020, Pacific Edge was not included in the
Local Coverage Determination (LCD) and as a result, did not normally receive any amounts for tests performed
for patients covered by CMS. On 3 July 2020, Pacific Edge received notice of inclusion in the LCD, resulting in
the Company receiving reimbursement for Cxbladder Monitor and Detect tests performed after 1 July 2020 for
patients covered by the CMS across the US that are deemed medically necessary.
For uninsured patients, the Group has no certainty of when or if the patient will pay.
Rest of World Customers
Revenue from Rest of World customers is primarily from Te Whatu Ora Health New Zealand. In all Rest Of World
locations, there is a clearly defined contract with the customer meeting the requirements of NZ IFRS 15. Pacific
Edge Diagnostics New Zealand Limited has individual contracts with regions across New Zealand and revenue is
recognised as described on the following pages.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
11
Notes to the Consolidated Financial Statements
For the year ended 31 March 2023
Critical Accounting Estimate
The application of NZ IFRS 15: Revenue from contracts with customers (NZ IFRS 15) requires the application of
significant judgement in determining whether the Group meets the five key criteria identified in NZ IFRS 15, which
must be met before revenue may be recognised as performance obligations are satisfied. For the Group this would
result in some revenue recognised in advance of the receipt of cash.
The significant judgements adopted by the Group relate to :
- determining if a contract with the customer exists;
- identifying the rights of each party;
- identifying the payment terms;
- ensuring the contract has commercial substance; and
- determining whether it is probable that the Group will collect the consideration to which it is entitled.
While there has been significant judgement applied to all five criteria, there are two criteria that have higher levels
of uncertainty, requiring increased levels of judgement. The significant judgements applied to determine the
Transaction Price and determining the probability of collecting consideration are detailed in the Accounting Policy
relating to Revenue from Cxbladder Tests.
ACCOUNTING POLICY
Revenue from Cxbladder tests – USA
The Group performs Cxbladder tests when requested by a patient’s physician. At the point the test results are
returned to the physician, the Group has satisfied its performance obligation and has the right to issue an invoice.
The Group has determined a contract exists, and payment terms are identified, the contract has commercial
substance and the rights of each party have been identified.
On 3 July 2020, Pacific Edge received notice of inclusion in the LCD, resulting in the Company receiving
reimbursement for Cxbladder Monitor and Detect tests performed after 1 July 2020 for patients covered by
the CMS across the US that are deemed medically necessary. Reimbursement for these tests is at the already
determined national CMS price for Cxbladder of US$760 per test, less a 2% sequestration fee.
Since Cxbladder’s inclusion in the LCD, based on historical data, the Group has been able to reliably estimate
both the probability and size of payment received from the CMS. The inclusion within the LCD combined with the
growing support for the use of Cxbladder within the US has also allowed the Group to reliably estimate both the
probability and size of payment received from customers covered by Medicare Advantage policies provided by
private insurers and for the year ended 31 March 2023 for customers covered by Kaiser Permanente. The change
relating to Kaiser Permanente in the year ended 31 March 2023 has resulted in an increase to operating revenue
and receivables of $418,000.
Tests performed for patients covered by other private policies, or tests performed for those with no insurance
cover continue to be recognised as revenue when cash is received due to not being able to reliably estimate both
probability and size of payment received.
The Group have concluded that the contracts with the CMS and customers covered by Medicare Advantage and
Kaiser Permanente include variable consideration because the amounts paid by Medicare or the commercial
health insurance carriers that provide Medicare Advantage and Kaiser Permanente may be paid at less than our
standard rates or not paid at all, with such differences considered implicit price concessions. Variable consideration
attributable to these price concessions is measured at the expected value, and are determined by historical average
collection rates by test type and payor category taking into consideration the range of possible outcomes, and the
predictive value of our past experiences. Such variable consideration is included in the transaction price only to the
extent it is probable that a significant reversal in the amount of cumulative revenue recognised will not occur.
As a result of the Significant Judgements applied, the Group have determined the criteria under NZ IFRS 15 which
allows revenue to be recognised in advance of the receipt of cash have been met, and the Group has recognised
revenue for tests which were performed from 1 October 2022 to 31 March 2023 (6 months prior to balance date)
for which payment has not been received by 31 March 2023 for CMS, Medicare Advantage and Kaiser Permanente.
Kaiser Permanente revenue was recognised on receipt of cash in the prior year.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
12
Notes to the Consolidated Financial Statements
For the year ended 31 March 2023
Rest of World revenue recognition from tests performed
There has been no change in accounting policy or estimates for Operating Revenue for the Rest of World.
The Group performs Cxbladder tests when requested by a patient’s physician in New Zealand, Australia and
Singapore. At the point the test results are returned to the physician, the Group has satisfied its performance
obligations have been met. At the end of the month an invoice is issued to the customer based on the number of
tests performed. Revenue is recognised when the invoice is issued.
OTHER INCOME
Grant Income
Government Grants are not recognised until there is reasonable assurance that the Group will comply with the
conditions attached to them and that the grants will be received. Government Grants are recognised in Other
Income in the consolidated statement of comprehensive income, on a systematic basis over the periods in which
the Group recognises the related costs as expenses for which the grants are intended to compensate.
The Company receives grants from Callaghan Innovation for postgraduate internships and summer students.
All conditions of the grants have been complied with.
Research Rebates and Tax Incentives
- New Zealand R&D Tax Incentive (RDTI)
The New Zealand RDTI is a 15% tax credit on the money invested in eligible research and development (R&D) that
has occurred in New Zealand. As the New Zealand companies are in a tax loss position, the Group is eligible for the
Tax Incentive to be refunded.
The RDTI is recognised at its fair value where there is a reasonable assurance that the credit will be received and
the Group will comply with all attached conditions.
All conditions of the New Zealand RDTI have been complied with. Payment will be received after submission of
each annual research and development tax claim.
- Australia Cxbladder Research Rebate
A Cxbladder research programme is administered by Pacific Edge (Australia) Pty Limited and tax rebates are
received as a result of this programme.
The Cxbladder research rebate is recognised at its fair value where there is a reasonable assurance that the rebate
will be received and the Group will comply with all attached conditions.
All conditions of the research rebate have been complied with. Payment will be received after submission of each
annual research and development tax claim.
REVENUE AND OTHER INCOME
2023
($000)
2022
($000)
Cxbladder Sales
– US- Accrual Accounting16,362 9,687
– US- Cash Accounting2,388 953
– Total US Sales 18,750 10,640
– Rest Of World 866 805
Total Operating Revenue 19,616 11,445
Other Income
Grant Revenue 44 321
Research Rebates and Tax Incentives 1,373 1,370
Total Other Income 1,417 1,691

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
13
Notes to the Consolidated Financial Statements
For the year ended 31 March 2023
6. RESEARCH AND DEVELOPMENT COSTS
ACCOUNTING POLICY
Research is the original and planned investigation undertaken with the prospect of gaining new scientific
knowledge and understanding. This includes: direct and overhead expenses for diagnostic and prognostic
biomarker discovery and research; pre-clinical trials; and costs associated with clinical trial activities. All research
costs are expensed when incurred.
Development is the application of research findings to a plan or design for the production of new or substantially
improved processes or products prior to the commencement of commercial production.
When a project reaches the stage where it is probable that future expenditure can be recovered through the
process or products produced, expenditure that is directly attributed or reasonably allocated to that project is
recognised as a development asset within intangible assets. If the expenditure also benefits processes or products
for which it cannot be recovered, it will be expensed. The asset will be amortised from the date of commencement
of commercial production of the product to which it relates on a straight-line basis over the period of expected
benefit. Development assets are reviewed annually for any impairment in their carrying value.
GROUP
Notes
2023
($000)
2022
($000)
Research Expenses 8,484 5,135
Includes:
Employee Benefits8 4,930 2,664
7. GENERAL AND ADMINISTRATION EXPENSES
GROUP
Notes
2023
($000)
2022
($000)
Amortisation14 213 78
Auditors Remuneration: PricewaterhouseCoopers New Zealand
- Group year end financial statements
- Half year review of financial statements
- Singapore Statutory financial statements
184
30
12
172
28
12
Auditors Remuneration: PricewaterhouseCoopers Singapore
- Statutory financial statements 15 12
Depreciation13 263 132
Depreciation on Right of Use Assets23 187 176
Directors Fees22 495 413
Employee Benefits8 4,990 3,216
Insurance 501 418
Interest on Lease Liabilities23 13 23
NZX, ASX and Registry Fees 305 901
Other Operating Expenses 2,925 2,175
10,133 7,756
Note: Amounts displayed for Amortisation, Depreciation, Employee Benefits are only the General and Administration Expenses
component of the total expenses. Refer to relevant notes for full expense disclosure.
Other Operating Expenses
The major categories of expenditure which make up General and Administration Expenses, but are not disclosed
separately above are Information Technology costs, Compliance and Regulatory costs, Investor Relations costs,
Consultants and Contractors.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
14
Notes to the Consolidated Financial Statements
For the year ended 31 March 2023
8. EMPLOYEE BENEFITS
GROUP
Notes
2023
($000)
2022
($000)
Represented by:
Employee Benefits:
Employee Benefits in Lab Operations 2,4802,145
Employee Benefits in Research64,9302,664
Employee Benefits in Sales and Marketing15,1559,848
Employee Benefits in General and Administration74,9903,216
Total Employee Benefits27,55517,873
Employee Share Scheme
The Company has an Employee Share Scheme where ordinary shares in the Company may be issued to selected
employees to recognise performance or a significant contribution to the Company. These shares may be issued
in lieu of a cash bonus or in addition to the employee’s remuneration. The ordinary shares are issued directly to
the employee and the Company accounts for the cost of the shares. The shares are allocated to the employee on
the date that the Board approves the issue of the share capital. All employees who hold ordinary shares in the
Company must comply with the Company’s Share Trading Policy.
The issuance of ordinary shares to employees is treated as equity settled share-based payments. Equity-settled
share-based payments to employees are measured at the fair value of the equity instruments at the grant date
based on the market price at the time of issuance. The fair value of shares granted is recognised as an employee
expense in the Consolidated Statement of Comprehensive Income when the shares are issued. During the 2023
financial year, 278,000 (2022: 123,000) ordinary shares were issued to employees as part of the Employee Share
Scheme. The associated non-cash cost of these shares was $182,000 (2022: $172,000). Refer to Note 18 for further
details on the shares issued during the financial year.
Attract and Retain Options
The Board believes that the issue of share options provides an appropriate incentive for participating employees to
grow the total shareholder return of the Company.
Attract and retain options are issued to selected employees as a long-term component of remuneration in
accordance with the Group’s remuneration policy. Incentive Options entitle the holder, on payment of the exercise
price, to one ordinary share of the Company.
The exercise price of the granted options is determined using the fair value of the Company’s share price at the
time of the options being granted.
Incentive Options issued prior to 31 March 2022 generally vest over three years and contain the requirement to
remain as an employee of the Company in order for the options to vest. Tranches of options are exercisable over
four to ten years from the relevant vesting date. No options can be exercised later than the tenth anniversary of the
final vesting date.
Options issued after 1 April 2022 generally vest equally in three trances over a four year period, with 1/3 on the
second, third and fourth anniversary of the issue. The Options are exercisable up to four years after vesting date.
Option holders are required to remain as an employee of the Company in order for options to vest. No options can
be exercised later than the fourth anniversary of the final vesting date. The exercise price increases annually for
each vested tranche at the equity cost of capital.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
15
Notes to the Consolidated Financial Statements
For the year ended 31 March 2023
ACCOUNTING POLICY
All options are accounted for as equity settled share based payments as the Group has no legal or constructive
obligation to repurchase or settle in cash. The fair value of all options granted is recognised as an expense in the
Consolidated Statement of Comprehensive Income over their vesting period, with a corresponding increase in the
employee share option reserve.
The fair value is determined at the grant date of the options and expensed on a straight-line basis over the vesting
period, based on the Group’s estimate of equity instruments that will eventually vest, with a corresponding increase
in equity. At the end of each reporting period, the Group revisits its estimate of the number of equity instruments
expected to vest. The impact of the revision of the original estimates, if any, is recognised in the Consolidated
Statement of Comprehensive Income such that the cumulative expense reflects the revised estimate, with a
corresponding adjustment to the share based payments reserve. The options expense for the year ended 31 March
2023 was $1,273,000 (2022: $839,000).
During the financial year ended 31 March 2023, there were no share options exercised (2022: 5,527,000). There was
no resulting increase in share capital (2022: $4,040,000). Refer to note 18 for further details on the share options
that were exercised in the year ended 31 March 2022.
Movements in the number of options outstanding and their related weighted average exercise prices are as follows:
GROUP
20232022
Weighted average
exercise price
$
Options
#
Weighted average
exercise price
$
Options
#
Outstanding at 1 April 0.60 13,861,319 0.42 15,952,289
Granted 0.60 4,293,215 1.23 3,682,500
Forfeited 1.04 (389,496)0.32 (246,076)
Exercised*- - 0.42 (5,527,394)
Expired- - - -
Outstanding at 31 March 0.59 17,765,038 0.60 13,861,319
Exercisable at 31 March 0.40 10,792,501 0.27 9,908,171
* There were no options exercised for the financial year ended 31 March 2023. The weighted average share price at the date of
options exercised during the year ended 31 March 2022 was NZ$1.35.
The Group used the Black-Scholes valuation model to determine the fair value of the equity instruments granted.
The Black-Scholes valuation model has been determined as the most appropriate method as it estimates the
theoretical value of options taking into account the impact of time and other risk factors. The significant inputs
into the Black-Scholes valuation model were the market share price at grant date, the exercise price shown below,
the expected annualised volatility of 50-70%, a dividend yield of 0%, an expected option life of between one and
ten years and an annual risk-free interest rate of between 0.65% and 4.94%.
The volatility measured is the standard deviation of continuously compounded share returns and is based on a
statistical analysis of daily share prices in the past one to ten years.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
16
Notes to the Consolidated Financial Statements
For the year ended 31 March 2023
Share options outstanding at the end of the reporting periods have the following expiry dates, vesting dates,
exercise prices and movements for the year ended 31 March 2023:
IssuedExpiryLow Exercise Price ($)High Exercise Price ($)Weighted Average Exercise Price ($)Opening Options as at 1 April 2022IssuedForfeitedExercisedExpiredClosing Options 31 March 2023Exercisable as at 31 March 2023
Apr 2014-
Mar 2015
Sept 2024-
Jan 2028
0.69 0.72 0.71 528,441 - - - - 528,441 528,441
Apr 2015-
Mar 2016
Sept 2025-
Mar 2029
0.50 0.60 0.51 332,399 - - - - 332,399 332,399
Apr 2016-
Mar 2017
Nov 2026-
Jan 2030
0.48 0.60 0.57 327,607 - - - - 327,607 327,607
Apr 2017-
Mar 2018
May 2028-
Feb 2031
0.28 0.51 0.50 2,770,899 - - - - 2,770,899 2,770,899
Apr 2018-
Mar 2019
Jun 2029-
Nov 2031
0.23 0.28 0.24 69,098 - - - - 69,098 69,098
Apr 2019-
Mar 2020
Aug 2030-
Aug 2032
0.23 0.23 0.23 4,037,267 - - - - 4,037,267 4,037,264
Apr 2020-
Mar 2021
Jun 2031-
Jun 2033
0.22 0.80 0.31 2,163,112 - (21,004) - - 2,142,108 1,478,052
Apr 2021-
Mar 2022
Aug 2032-
Aug 2034
1.23 1.23 1.23 632,496 - (278,881)- - 353,615 165,278
Apr 2021-
Mar 2022
Feb 2027-
Feb 2031
1.15 1.25 1.23 3,000,000 - - - - 3,000,000 600,000
Apr 2022-
Mar 2023
Dec 2026-
Dec 2030
0.48 0.70 0.60 - 4,293,215 (89,611)- - 4,203,604 483,463
TOTALS 0.59 13,861,319 4,293,215 (389,496) - - 17,765,038 10,792,501

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
17
Notes to the Consolidated Financial Statements
For the year ended 31 March 2023
9. CASH, CASH EQUIVALENTS AND SHORT TERM DEPOSITS
ACCOUNTING POLICY
Cash and cash equivalents includes cash in hand and deposits held on call with banks, and bank overdrafts. Term
deposits are also presented as cash equivalents if they have a maturity of three months or less from acquisition
date.
Short Term Deposits and Cash Equivalents include investments with ANZ, BNZ, Kiwibank and Westpac (2022: ANZ,
BNZ, Kiwibank and Westpac), with periods ranging up to 365 days. Funds held on term deposit with ANZ, BNZ
Westpac and Kiwibank can be accessed with one month’s notice at the request of the authorised bank signatories
of Pacific Edge Limited, but may incur fees and/or charges for early access.
GROUP
2023
($000)
2022
($000)
Cash and Cash Equivalents33,22935,412
Short Term Deposits44,56270,000
Total Cash, Cash Equivalents and Short Term Deposits77,791105,412
NZD55,95484,517
USD20,39918,601
AUD1,4292,284
EUR21
SGD79
Total Cash, Cash Equivalents and Short Term Deposits77,791105,412
INTEREST INCOME
ACCOUNTING POLICY
Interest income is recognised using the effective interest method.
Interest on the bank balances ranges from 0% to 5.99% (2022: 0% to 1.89%) per annum.
10. RECEIVABLES
ACCOUNTING POLICY
Receivables are initially measured at fair value and subsequently measured at amortised cost using the effective
interest rate method, less any provision for impairment. An allowance for impairment is made up of expected
credit losses based on the assessment of the trade receivables debt at the individual level for impairment, plus an
additional allowance on the remaining balance for potential credit losses not yet identified.
GROUP
2023
($000)
2022
($000)
Trade Receivables 2,780 1,633
Sundry Debtors 2,257 1,925
Accrued Interest 383 337
GST Refund Due 73 117
Total Receivables 5,493 4,012

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
18
Notes to the Consolidated Financial Statements
For the year ended 31 March 2023
There is no provision for impairment relating to the revenue from Cxbladder sales in New Zealand. All outstanding
sales are current and there are no expected credit losses on the amounts outstanding at balance date.
US Trade Receivables includes a provision for future refunds of $271,000 (2022: $143,000).
Sundry Debtors include accruals for grants and rebates that have not yet been paid. These are expected to be paid
once the relevant claims have been submitted. The Company has met all conditions of the claims and there is no
indication that there is impairment of these balances.
Included in trade receivables are the below amounts which were past due but not impaired. These relate to a
number of customers for whom there is no history of default.
GROUP
2023
($000)
2022
($000)
3 to 6 Months 436 109
Total Overdue Trade Receivables 436 109
The foreign currency split of Receivables is:
GROUP
2023
($000)
2022
($000)
NZD 2,375 1,579
USD 2,685 1,550
AUD 433 883
Total Receivables 5,493 4,012
11. INVENTORY
ACCOUNTING POLICY
Inventories are stated at the lower of cost and net realisable value. Cost is determined using the weighted average
formula.
GROUP
2023
($000)
2022
($000)
Laboratory Supplies 1,287 1,007
Total Inventory 1,287 1,007
The major items of Inventory are laboratory reagents, chemicals and Cxbladder urine sampling systems.
Laboratory supplies used during the year of $2,540,000 (2022: $1,569,000) are included within the Consolidated
Statement of Comprehensive Income in Laboratory Operations and Research.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
19
Notes to the Consolidated Financial Statements
For the year ended 31 March 2023
12. OTHER ASSETS
GROUP
2023
($000)
2022
($000)
Prepayments
1,156 1,014
Security Deposits
244 169
Total Other Assets
1,400 1,183
Prepayments are largely made up of insurance, industry conferences, subscriptions and travel not used. Security
deposits are paid to secure properties for lease in the US and Singapore and to secure credit cards in the US.
13. PROPERTY, PLANT AND EQUIPMENT
ACCOUNTING POLICY
Property, Plant and Equipment are those assets held by the Group for the purpose of carrying on its business
activities on an ongoing basis. All Property, Plant and Equipment is stated at cost less subsequent accumulated
depreciation and any accumulated impairment losses. The cost of purchased assets includes the original purchase
consideration given to acquire the assets, and the value of other directly attributable costs that have been
incurred in bringing the assets to the location and condition necessary for their intended service. This includes the
laboratory equipment for the establishment of the laboratories.
Gains and losses on disposals are determined by comparing the net proceeds with the carrying amount and are
recognised within the Consolidated Statement of Comprehensive Income when they occur.
Depreciation
Depreciation of plant and equipment is based on writing off the assets over their useful lives, using the straight line
(SL) and diminishing value (DV) basis.
Main rates used are:
Plant and Laboratory Equipment 5% to 40% DV
Computer Equipment 5% to 67% DV
Leasehold Improvements 6% to 10% SL
Furniture and Fittings 5% to 25% DV
The assets’ useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
20
Notes to the Consolidated Financial Statements
For the year ended 31 March 2023

Plant &
Laboratory
Equipment
($000)
Computer
Equipment
($000)
Leasehold
Improvements
($000)
Furniture
& Fittings
($000)
Total
($000)
Cost
Balance at 1 April 20212,1935123372993,341
Additions51123221333989
Disposals (788) (362) (159) (7) (1,316)
Translation Difference12115
Balance at 31 March 20221,9173843923263,019
Balance at 1 April 20221,9173843923263,019
Additions1,53525912671,873
Disposals (48) (64) (23) (123) (258)
Translation Difference371815171
Balance at 31 March 20233,4415973962714,705
Accumulated Depreciation
Balance at 1 April 2021 1,824 439 155 235 2,653
Depreciation Expense 150 89 14 10 263
Disposals (787) (355) (71) (91) (1,304)
Translation Difference 2 1 - - 3
Balance at 31 March 20221,189174981541,615
Balance at 1 April 2022 1,189 174 98 154 1,615
Depreciation Expense 332 136 33 26 527
Disposals (177) (69) 57 (58) (247)
Translation Difference 23 8 9 2 42
Balance at 31 March 20231,3672491971241,937
Carrying Amounts
At 1 April 2021 369 73 182 64 688
At 31 March 2022 728 210 294 172 1,404
At 31 March 2023 2,074 348 199 147 2,768

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
21
Notes to the Consolidated Financial Statements
For the year ended 31 March 2023
14. INTANGIBLE ASSETS
ACCOUNTING POLICY
Intellectual Property
The costs of acquired Intellectual Property are recognised at cost. All Intellectual Property has a finite life. The carrying
value of Intellectual Property is reviewed for impairment, where indicators of impairment exist. Amortisation is charged
on a diminishing value basis over the estimated useful life of the intangible assets (1-20 years). The estimated useful life
and amortisation method is reviewed at the end of each reporting period.
The following costs associated with Intellectual Property are expensed as incurred during the research phases of
a project and are only capitalised when incurred as part of the development phase of a process or product within
development assets: Internal Intellectual Property costs including the costs of patents and patent application.
Software Development Costs
Costs associated with the development of software are held at cost. Amortisation is charged on a diminishing value
basis over the estimated useful life of the intangible assets (2-10 years). The estimated useful life and amortisation
method is reviewed at the end of each reporting period.
Cxbladder Development Costs
Costs associated with the development of Cxbladder products have been removed as an Intangible Asset during the
financial year with the $13,000 remaining value expensed in the Consolidated Statement of Comprehensive Income for
the year ended 31 March 2023.
Software
Development
Costs
($000)
Patents
($000)
Cxbladder
Development
Costs
($000)
Total
($000)
Cost
Balance at 1 April 2021921415331,369
Additions278135- 413
Foreign Translation Difference- - - -
Balance at 31 March 20221,199550331,782
Balance at 1 April 20221,199550331,782
Additions97773- 1,050
Disposals(12)(33)(45)
Foreign Translation Difference4- - 4
Balance at 31 March 20232,168623-2,791
Accumulated Amortisation
Balance at 1 April 2021846328181,192
Amortisation Expense87672156
Foreign Translation Difference- - - -
Balance at 31 March 2022933395201,348
Balance at 1 April 2022933395201,348
Amortisation Expense35968- 427
Disposals- - (20)(20)
Foreign Translation Difference5- - 5
Balance at 31 March 20231,297463-1,760
Carrying Amounts
At 31 March 2021758715177
At 31 March 202226615513434
At 31 March 2023871160-1,031

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
22
Notes to the Consolidated Financial Statements
For the year ended 31 March 2023
15. SEGMENT INFORMATION
Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating
decision-maker. The chief operating decision-maker, who is responsible for allocating resources and assessing
performance of the operating segments, has been identified as the Chief Executive Officer who makes strategic
decisions.
There are two operating segments at balance date:
1. Commercial: The sales, marketing, laboratory and support operations to run the commercial businesses worldwide.
2. Research: The research and development of diagnostic and prognostic products for human cancer.
The reportable operating segment Commercial derives its revenue primarily from sales of Cxbladder tests and
the reportable operating segment Research derives its revenue primarily from grant income. The Chief Executive
Officer assesses the performance of the operating segments based on their net loss for the period.
Segment income, expenses and profitability are presented on a gross basis excluding inter-segment eliminations
to best represent the performance of each segment operating as independent business units. The segment
information provided to the Chief Executive Officer for the reportable segment described above, for the year
ended 31 March 2023, is shown below.
2023
Commercial
($000)
Research
($000)
Less:
Eliminations
($000)
Total External
Income
($000)
Income
Operating Revenue – External19,616- - 19,616
Other Income4672,245 (1,295)1,417
Interest Income182,743- 2,761
Foreign Exchange Gain52,325- 2,330
Total Income20,1067,313 (1,295)26,124
Expenses
Expenses35,89116,360 (1,295)50,956
Depreciation & Amortisation1,311822-2,133
Total Operating Expenses37,20217,182 (1,295)53,089
Loss Before Tax (17,096) (9,869)- (26,965)
Income Tax Expense----
Loss After Tax (17,096) (9,869)- (26,965)
Net Cash Flow to Operating Activities (15,908) (9,667)- (25,575)

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
23
Notes to the Consolidated Financial Statements
For the year ended 31 March 2023
2022
Commercial
($000)
Research
($000)
Less:
Eliminations
($000)
Total External
Income
($000)
Income
Operating Revenue – External 11,445 - - 11,445
Other Income 437 2,187 (933) 1,691
Interest Income 2 547 - 549
Foreign Exchange Gain- 193 - 193
Total Income 11,884 2,927 (933) 13,878
Expenses
Expenses 20,378 12,737 (933) 32,182
Depreciation and Amortisation 977 507 - 1,484
Total Operating Expenses 21,355 13,244 (933) 33,666
Loss Before Tax (9,471) (10,317)- (19,788)
Income Tax Expense- - - -
Loss After Tax (9,471) (10,317)- (19,788)
Net Cash Flow to Operating Activities (8,620) (8,932)- (17,552)
Eliminations
These are the intercompany transactions between the subsidiaries and the Parent. These are eliminated on
consolidation of Group results. The Research segment of the business utilise consumables and other components
that are purchased by the Commercial segments of the business, with the costs of these components allocated to
Research segment, and the Commercial segment recognising revenue from the sale.
Segment Assets and Liabilities Information
2023
Commercial
($000)
Research
($000)
Total
($000)
Total Assets 9,375 81,538 90,913
Total Liabilities 5,853 2,297 8,150

2022
Commercial
($000)
Research
($000)
Total
($000)
Total Assets 6,031 109,251 115,282
Total Liabilities 4,571 2,335 6,906
Additions to Non Current Assets for the period include:
Commercial
($000)
Research
($000)
Total
($000)
Property, Plant and Equipment 1,785 88 1,873
Right of Use Assets 337 - 337
Intangible Assets 966 73 1,039
Total Additions to Non Current Assets 3,088 161 3,249
The amounts provided to the Chief Executive Officer with respect to total assets and total liabilities are measured
in a manner consistent with that of the financial statements. These assets and liabilities are allocated based on the
operation of the segment and the physical location of the asset.
There are no unallocated assets or liabilities.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
24
Notes to the Consolidated Financial Statements
For the year ended 31 March 2023
Geographic Split of Revenue and Non-Current Assets
The Group generates most of the operating revenue from Commercial tests from the US and New Zealand, and
also receives Grant revenue from Australia and New Zealand. Rest of World consists of Revenue from Australia and
Singapore.
2023
($000)
2022
($000)
Operating and Grant Revenue
US 18,750 10,640
New Zealand 1,611 1,729
Rest of World 672 767
Total Operating and Grant Revenue 21,033 13,136
2023
($000)
2022
($000)
Non-Current Assets
US 1,907 1,611
New Zealand 3,035 2,057
Rest of World- -
Total Non-Current Assets 4,942 3,668
16. INCOME TAX
ACCOUNTING POLICY
The tax expense for the period comprises current and deferred tax. Tax is recognised in the Consolidated
Statement of Comprehensive Income, except to the extent that it relates to items recognised in other
comprehensive income or directly in equity. In this case, the tax is also recognised in other comprehensive income
or directly in equity, respectively.
The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the
balance sheet date in the countries where the Company and its subsidiaries operate and generate taxable income.
Management periodically evaluates positions taken in tax returns with respect to situations in which applicable
tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts
expected to be paid to the tax authorities.
Deferred income tax is provided in full, using the liability method, on temporary differences arising between the
tax bases of assets and liabilities and their carrying amounts in the financial statements in accordance with NZ
IAS 12. Deferred income tax assets are recognised to the extent that it is probable that future taxable profit will be
available against which the temporary differences can be utilised.
Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by
the balance sheet date and are expected to apply when the related deferred income tax asset is realised or the
deferred income tax liability is settled.
The Company and Group has incurred an operating loss for the 2023 financial year and no income tax is payable.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
25
GROUP
2023
($000)
2022
($000)
Income tax recognised in the Statement of Comprehensive
income

Current tax expense- -
Deferred Tax in respect of the Current Year (3,748) (4,258)
Adjustments to deferred tax in respect to Prior Years 137 94
Deferred Tax Assets not recognised 3,611 4,164
Income tax expense- -

The prima facie income tax on Pre-Tax Accounting Profit
from operations reconciles to:
Accounting loss before income tax (26,965) (19,788)
At the statutory Income Tax rate of 28% (7,550) (5,541)
Non-deductible Expenses 5,007 626
Difference in US, Singapore and Australian Income Tax Rates 1,211 657
Prior Period Adjustment 138 94
Tax Losses Utilised (2,417)-
Deferred Tax Assets not recognised 3,611 4,164
Income tax expense reported in the Statement of
Comprehensive income
- -
Tax Losses
The group has losses to carry forward of approximately $130,444,000 (2022: $112,330,000) with a potential tax
benefit of $28,913,000 (2022: $25,694,000). The tax losses are split between the following jurisdictions:
Tax Losses
($000)
Tax Effect
($000)Rate
New Zealand 20,800 5,800 28%
Australia 1,500 500 30%
Singapore 2,000 300 17%
United States 106,000 22,300 21%
Tax losses are available to be carried forward and offset against future taxable income subject to the various
conditions required by income tax legislation being complied with.
Deferred Research and Development Tax Expenditure:
The Group also has deferred research and development tax expenditure of $51,462,000 (2022: $45,846,000) to
carry forward and claim for income tax purposes in New Zealand in the future. This has a tax effect of $14,409,000
(2022: $12,889,000). The deferred research and development tax expenditure can either be carried forward and
offset against future income arising from the research and development, or subject to meeting the shareholder
continuity requirements can be offset against future other taxable income.
Deferred Tax Assets:
The Group does not recognise a deferred tax asset in the Consolidated Balance Sheet.
Imputation Credit Account
The Group has imputation credits of Nil (2022: Nil).
Notes to the Consolidated Financial Statements
For the year ended 31 March 2023

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
26
17. PAYABLES AND ACCRUALS
ACCOUNTING POLICY
Trade and Other Payables Due Within One Year
Trade payables are recognised at the value of the invoice received from a supplier. The carrying value of trade
payables is considered to approximate fair value as amounts are unsecured and are usually paid by the 30th of the
month following recognition.
GROUP
2023
($000)
2022
($000)
Trade Creditors 2,178 1,906
Accrued Expenses 1,087 659
Employee Entitlements (refer below) 3,663 2,418
Total Payables and Accruals 6,928 4,983
Payables and accruals are non-interest bearing and are normally settled on 30 day terms, therefore their carrying
value approximates their fair value.
The foreign currency split for Payables and Accruals is:
GROUP
2023
($000)
2022
($000)
NZD 2,067 2,161
AUD 299 131
USD 4,521 2,656
SGD 41 35
6,928 4,983
Employee Entitlements
Employee entitlements are measured at values based on accrued entitlements at current rates of pay. These include
salaries and wages accrued up to balance date and annual leave earned to, but not yet taken at balance date.
GROUP
2023
($000)
2022
($000)
Income Tax 291 214
Holiday Pay 565 360
Accrued Wages 2,807 1,844
Total Employee Entitlements 3,663 2,418
Notes to the Consolidated Financial Statements
For the year ended 31 March 2023

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
27
18. SHARE CAPITAL
ACCOUNTING POLICY
Ordinary shares are described as equity.
Issue expenses, including commission paid, relating to the issue of ordinary share capital, have been written off
against the issued share price received and recorded in the Consolidated Statement of Changes in Equity.
Equity-settled share-based payments to employees and others providing services are measured at the fair value
of the equity instruments at the grant date. Details regarding the determination of the fair value of equity-settled
share based transactions are set out in Note 8.
GROUP
2023
($000)
2022
($000)
Ordinary Shares Authorised 294,317 294,139
Total Share Capital 294,317 294,139
All fully paid shares in the Group are Authorised and have equal voting rights and equal rights to dividends. All
Ordinary Shares are fully paid and have no par value.
Share Capital Group
2023 Shares
(000)
2023
($000)
2022 Shares
(000)
2022
($000)
Opening Balance 810,087 294,139 727,779 190,305
Issue of Ordinary Shares
- Placement
1
- Exercise of Share Options
2
- Employee Remuneration
3
-
-
278
-
-
182
76,657
5,528
123
103,487
4,040
172
Less: Issue Expenses
- (4)- (3,865)
Movement 278 178 82,308 103,834
Closing Balance 810,365 294,317 810,087 294,139

1) During the period no shares were issued under placements (2022: 76,657,358 at $1.35 per share)
2) During the period no share options were exercised (2022: 5,527,391 at an average price of $0.42)
3) During the period 277,985 shares were issued as part of employees remuneration in lieu of cash payments at an average price
of $0.65 per share. (2022: 123,086 at $1.40)
Notes to the Consolidated Financial Statements
For the year ended 31 March 2023

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
28
19. FOREIGN CURRENCY
ACCOUNTING POLICIES
Foreign Currency Transactions
The individual financial statements of the Group are presented in the currency of the primary economic
environment in which the entity operates (its functional currency). For the purpose of the Group financial
statements, the results and financial position of the Group entity are expressed in New Zealand dollars (‘NZ$’),
which is the functional currency of the Parent and the presentation currency for the Group financial statements.
In preparing the financial statements of the individual entities, transactions in currencies other than the entity’s
functional currency (foreign currencies) are recorded at the rates of exchange prevailing at the dates of the
transactions. At the end of each reporting period, monetary items denominated in foreign currencies are
retranslated at the rates prevailing at the end of the reporting period. Non monetary items denominated in foreign
currencies are translated at the rates prevailing on the date the transaction occurs.
Exchange differences are recognised in the Consolidated Statement of Comprehensive Income in the period in
which they arise.
Foreign Operations
For the purpose of presenting the Group financial statements, the assets and liabilities of the Group’s foreign
operations are expressed in New Zealand dollars using exchange rates prevailing at the end of the reporting
period. Income and expense items are translated at the average exchange rates for the period, unless exchange
rates fluctuated significantly during that period, in which case the exchange rates at the dates of the transactions
are used. Exchange differences arising, if any, are recognised in other comprehensive income and accumulated as
a separate component of equity in the Group’s foreign currency translation reserve. Such exchange differences
are reclassified from equity to profit or loss (as a reclassification adjustment) in the period in which the foreign
operation is disposed of.
Foreign Currency Translation Reserve
Exchange differences relating to the translation from the functional currencies of the Group’s foreign subsidiaries into
New Zealand dollars are brought to account by entries made directly to the Foreign Currency Translation Reserve.
20. RECONCILIATION OF CASH FLOWS TO OPERATING ACTIVITIES WITH OPERATING NET LOSS
GROUP
2023
($000)
2022
$000
Net Loss for the Period (26,965) (19,788)
Add Non Cash Items:
Depreciation 527 263
Loss on disposal of Property, Plant and Equipment 24 11
Amortisation 427 156
Employee Share Options 1,273 839
Employee Bonuses paid in shares in lieu of cash 182 172
Depreciation on Right of Use Assets 1,179 1,064
Interest on finance leases shown in lease repayments 83 126
Total Non Cash Items 3,695 2,631
Add Movements in Other Working Capital items:
(Increase) in Receivables and Other Assets (1,641) (1,772)
Decrease in Inventory (280) (217)
Increase in Payables and Accruals 1,946 1,786
Effect of exchange rates on net cash (2,330) (192)
Total Movement in Other Working Capital (2,305) (395)
Net Cash Flows to Operating Activities (25,575) (17,552)
Notes to the Consolidated Financial Statements
For the year ended 31 March 2023

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
29
Notes to the Consolidated Financial Statements
For the year ended 31 March 2023
21. FINANCIAL INSTRUMENTS
ACCOUNTING POLICY
Foreign Currency Transactions
Financial instruments include cash and cash equivalents, short term deposits, receivables, security deposits, finance
lease liabilities and trade creditors. The particular recognition methods adopted are disclosed in the individual policy
statements associated with each item.
Managing Financial Risk
The Group’s activities expose it to the financial risks of changes in interest rate risk, credit risk, liquidity risk and
foreign currency risk. Management is of the opinion that the Company and the Group’s exposure to market risk
during the period and at balance date is defined as:
Risk FactorDescription
(i) Currency RiskFinancial assets and financial liabilities are denominated in NZD, USD, AUD, SGD and
EUR currencies
(ii) Interest Rate Risk Exposure to changes in Bank interest rates resulting in cash flow interest rate risk
(iii) Credit RiskRisk of financial loss if counterparty fails to meet contractual obligations
(iv) Liquidity RiskRisk the Group may not be able to meet its commitments as they fall due
(v) Other Price RiskNot applicable as no securities are bought, sold or traded
(i) Foreign Currency Risk
The Group faces the risk of movements in foreign currency exchange rates in relation to the New Zealand dollar.
The Group has significant operations in United States Dollars and less significant operations in Australian dollars,
Euros and Singapore dollars. As a result of this, the financial performance and financial position are impacted by
movements in exchange rates.
The Group manages foreign currency risk by purchasing overseas goods only when necessary and in line with the
approved treasury policy. It will also purchase foreign currency to fund overseas operations based on cash flow
forecasts in line with the approved treasury policy. There are no formal foreign currency hedges entered into.
A 10% increase or decrease in the foreign currency against the NZD will reduce/increase the loss reported by
approximately $337,000 (2022: $167,000) and increase/reduce equity by the same amount.
(ii) Interest Rate Risk
The Group’s interest rate risk arises from its cash and equivalents, and short term deposits. Cash and equivalents
comprise cash on hand and deposits at call with banks. Short term deposits comprise of term deposits placed with
New Zealand banks on fixed rates for different periods of time.
Management regularly review its banking arrangements to ensure it achieves the best returns on its funds while
maintaining access to necessary liquidity levels to service the Group’s day-to-day activities. The mixture of bank
deposits at floating interest rates and short term deposits at different rates over various periods of time mitigate the
risk of interest rates being received at less than market rates. The Group does not enter into interest rate hedges.
A 1% increase or decrease in bank deposit interest rates will reduce/increase the loss reported by approximately
$764,000 and increase/reduce equity by the same amount (2022: $1,041,000).
(iii) Credit Risk
Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument fails to
meet its contractual obligations.
The Group incurs credit risk from:
a) cash and short term deposits;
b) receivables in the normal course of its business; and
c) other assets.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
30
Notes to the Consolidated Financial Statements
For the year ended 31 March 2023
The Group has no significant concentration of credit risk other than bank deposits, with the exposure as at 31
March 2023 expressed as a percentage of total assets: 24.0% at ANZ, 22.1% at BNZ, 20.3% at Westpac, 18% at
Kiwibank and 1.2% at Wells Fargo. The Group’s cash and short term deposits are placed with high credit quality
financial institutions including major banks who have at least a A+ credit rating and concentrations are managed
within the approved treasury policy.
Regular monitoring of receivables is undertaken to ensure that the credit exposure remains within the Group’s
normal terms of trade. These receivables balances mainly relate to New Zealand customers, and the New Zealand
and Australian Government. Refer to note 10 for further details on expected credit losses for receivables.
The Group continues to invoice for every billable test completed in the US, and the billing and reimbursement
process continues to maximise the cash that is received by the Group. The Group has included an accrual for
tests performed from 1 October 2022 to 31 March 2023 for which payment has not been received by 31 March
2023.
Regular monitoring of other assets is undertaken to ensure that the credit exposure is limited.
The carrying values of financial assets represent the maximum exposure to credit risk as represented below:
GROUP
Notes
2023
($000)
2022
($000)
Cash and Cash Equivalents933,22935,412
Short Term Deposits944,56270,000
Trade and Other Receivables (excludes GST)105,4203,895
Other Assets (excludes prepayments)12 244 169
83,455109,476
(iv) Liquidity Risk
Liquidity risk is the risk that the Group may encounter difficulty in raising funds at short notice to meet its
commitments as they fall due. Management maintains sufficient cash balances and uses cash flow forecasts to
determine future cash flow requirements. Liquidity risk is managed within the approved treasury policy. The Group
does not have any external loans but does have four finance leases.
Payables and Accruals totaling $6,928,000 are due within 3 months of balance date (2022: $4,983,000).
Fair Values
In the opinion of the Directors, the carrying amount of financial assets and financial liabilities approximate their fair
values at balance date.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
31
Notes to the Consolidated Financial Statements
For the year ended 31 March 2023
22. RELATED PARTIES
A shareholder, the University of Otago, provided services, including rental space, car parking and use of University
Equipment, to the Group to the value of $407,000 (2022: $361,000). The Group has commitments totaling
$344,000 (2022: $269,000) with the University of Otago in the next financial year.
Key Management Compensation
Key management personnel comprise of Directors and the Chief Executive Officer of Pacific Edge Limited, and the
Chief Executive Officer and Executive Chairman of Pacific Edge Diagnostics USA Limited.
Refer to Note 8 for details of the Incentive Plan that includes key management remuneration.
GROUP
2023
($000)
2022
($000)
Salaries and Other Short Term Employee Benefits2,4832,207
Consulting Fees-105
Share Options Benefits907445
Total Employee Entitlements3,3902,757
Directors’ Fees
The current total Directors’ fee pool for non-executive Directors of Pacific Edge Limited, approved by the
shareholders at the Annual Shareholders Meeting on the 29th July 2021 was $465,000 per annum and was based
on six Directors. With the addition of Tony Barclay on 21 March 2022, the number of Directors increased to seven.
In accordance with NZX Listing Rule 2.11.3 which permits an issuer to increase the aggregate amount payable to
the Directors to take into account an additional Director without shareholder approval, the pool for non-executive
Directors of Pacific Edge increased to $529,000. The total amount of fees paid to Directors for the year ended 31
March 2023 was $495,000.
The table below sets out the total fees approved for non-executive Directors of Pacific Edge Limited for the year
ended 31 March 2023 based on the positions held:
Position
Quantity
2023
Fee per
Director
2023
($)
Total
Directors
Fees Paid
2023
($)
Quantity
2022
Fee per
Director
2022
($)
Total
Directors
Fees Paid
2022
($)
Chair1115,000115,0001115,000115,000
Deputy Chair 170,00070,000170,00070,000
Non-executive Directors560,000300,000460,000240,000
Chair Audit & Risk Committee110,00010,000110,00010,000
Special Governance Allocation---130,00030,000
Total Fee Pool495,000465,000

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
32
Notes to the Consolidated Financial Statements
For the year ended 31 March 2023
23. FINANCE AND OPERATING LEASE COMMITMENTS
ACCOUNTING POLICY
The group leases various properties and equipment. Rental contracts vary depending on the type of asset
being leased. Lease terms are negotiated on an individual basis and contain a wide range of different terms and
conditions. The lease agreements do not impose any covenants, but leased assets may not be used as security for
borrowing purposes.
Contracts may contain both lease and non-lease components. The Group allocates the consideration in the
contract to the lease and non-lease components based on their relative stand-alone prices.
Leases are recognised as a right-of-use asset and a corresponding liability at the date at which the leased asset is
available for use by the Group. Each lease payment is allocated between the liability and finance cost. The finance
cost is charged to the Consolidated Statement of Comprehensive Income over the lease period to produce a
constant periodic rate of interest on the remaining balance of the liability for each period. The right-of-use asset is
depreciated over the shorter of the asset’s useful life and the lease term on a straight-line basis.
(i) Measurement basis
Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the
net present value of the following lease payments:
• fixed payments (including in-substance fixed payments), less any lease incentives receivable;
• variable lease payments that are based on an index or a rate;
• amounts expected to be payable by the lessee under residual value guarantees;
• the exercise price of a purchase option if the lessee is reasonably certain to exercise that option; and
• payments of penalties for terminating the lease, if the lease term reflects the lessee exercising that option.
Lease payments to be made under reasonably certain extension options are also included in the measurement of
the liability.
The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be readily
determined, which is generally the case for leases in the group, the lessee’s incremental borrowing rate is used. The
incremental borrowing rate is the rate that the individual lessee would have to pay to borrow the funds necessary
to obtain an asset of similar value to the right-of-use asset in a similar economic environment with similar terms,
security and conditions.
To determine the incremental borrowing rate, the Group:
• where possible, uses recent third-party financing received by the individual lessee as a starting point, adjusted to
reflect changes in financing conditions since third-party financing was received;
• uses a build-up approach that starts with a risk-free interest rate adjusted for credit risk for leases held by Pacific
Edge Limited, which does not have recent third-party financing; and
• makes adjustments specific to the lease, e.g. term, country, currency and security.
The Group is exposed to potential future increases in variable lease payments based on an index or rate, which are
not included in the lease liability until they take effect. When adjustments to lease payments based on an index or
rate take effect, the lease liability is reassessed and adjusted against the right-of-use asset.
Lease payments are allocated between principal and finance cost. The finance cost is charged to the Consolidated
Statement of Comprehensive Income over the lease period to produce a constant periodic rate of interest on the
remaining balance of the liability for each period.
Right-of-use assets are measured at cost comprising the following:
• the amount of the initial measurement of lease liability;
• any lease payments made at or before the commencement date;
• any initial direct costs; and
• restoration costs.
Right-of-Use assets are generally depreciated over the shorter of the asset’s useful life and the lease term on
a straight-line basis. If the Group is reasonably certain to exercise a purchase option, the Right-of-Use asset is
depreciated over the underlying asset’s useful life.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
33
Notes to the Consolidated Financial Statements
For the year ended 31 March 2023
Payments associated with short-term leases and leases of low-value assets are recognised on a straight-line basis
as an expense in profit or loss. Short-term leases are leases with a lease term of 12 months or less. Low-value assets
include IT equipment and small items of office furniture.
Right of Use Assets
GROUP
2023
($000)
2022
($000)
Cost
Opening Balance 3,605 3,914
Additions 337 179
Removals (Leases Completed)- (366)
Foreign Currency Translation 249 (122)
Closing Balance 4,191 3,605

Accumulated Depreciation
Opening Balance 1,775 937
Depreciation 1,179 1,064
Reversal of Accumulated Depreciation (Leases Completed)- (153)
Foreign Currency Translation94 (73)
Closing Balance 3,048 1,775
Net Right of Use Assets Balance 1,143 1,830
Right of Use Assets Net Book Value
Buildings 1,128 1,792
Computer Equipment 15 38
Plant and Equipment- -
1,143 1,830
Depreciation
Buildings 1,152 1,018
Computer Equipment 27 24
Plant and Equipment- 22
1,179 1,064
Expenses relating to Short Term and Low Value Leases 115 74
Total Cash Outflow relating to Leases 1,278 1,273

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
34
Notes to the Consolidated Financial Statements
For the year ended 31 March 2023
GROUP
Lease Liability
2023
($000)
2022
($000)
Opening Balance 1,923 2,878
Additions337 148
Lease Terminated- Liability Reversed- -
Lease Repayments (1,286) (1,230)
Interest Charged 83 126
Foreign Currency Translation165 1
Closing Balance 1,222 1,923
Split by:
Current Liability 811 1,072
Non-Current Liability 411 851
1,222 1,923
The maturity of the Lease Liabilities is as follows:
Less than one year 811 1,072
One to two years 116 671
Two to three years 122 51
More than three years 173 129
1,222 1,923
24. OTHER COMMITMENTS AND CONTINGENT LIABILITIES
a) Contingent Liabilities
There were no known contingent liabilities at 31 March 2023 (March 2022: Nil). The Group has not granted any
securities in respect of liabilities payable by any other party whatsoever.
b) Capital Commitments
There are no capital commitments at 31 March 2023 (March 2022: Nil).
25. PROPOSED LOCAL COVERAGE DETERMINATION (LCD) AND LOCAL COVERAGE
ARTICLE (LCA) CHANGES - POTENTIAL IMPACT ON REVENUE
On 29 July 2022 Pacific Edge Limited became aware of proposed changes by Novitas, the Medicare Administrative
Contractor (MAC) with jurisdiction for Pacific Edge’s US laboratory to the Local Coverage Determination (LCD)
and Local Coverage Article (LCA) that governs the reimbursement of Cxbladder in the US by the US Centers for
Medicare & Medicaid Services (CMS).
If the proposed LCD (DL39365) and LCA (DA59125) were approved unchanged, Cxbladder would not qualify for
coverage from Novitas for tests reimbursed by the CMS. These tests represent a significant portion of current
Cxbladder testing revenue. Multiple companies that have existing coverage, or are seeking coverage, are similarly
impacted by this proposal.

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
35
Notes to the Consolidated Financial Statements
For the year ended 31 March 2023
Having consulted with US-based advisers and industry experts, Pacific Edge believes the proposed changes are
unlikely to survive the ongoing review process in their current form. The consensus view of those consulted by
Pacific Edge was that the proposed changes to the LCD/LCA are contrary to US legal requirements and precedent.
The proposed changes also fundamentally change the process for determining coverage for specific tests and
could deprive US clinicians and Medicare patients access to diagnostic tools with proven, peer-reviewed clinical
utility.
Novitas closed the period for public comments on the proposals on 6 September 2022. Novitas has not provided
a specific date for a decision, however Pacific Edge understands Novitas must either publish or withdraw the draft
LCD/LCA within a year of the date of proposal, being 28 July 2023. When publishing, Novitas is required to address
all comments from Pacific Edge and other companies, and at their discretion may elect to alter the text of the draft
LCD/LCA in response to those comments when publishing. Pacific Edge understands CMS is required to give at
least 45 days’ notice of the effective determination date.
Pacific Edge received payment in line with the existing LCD/LCA for the financial year ended 31 March 2023, and to
the date of approval of these Consolidated Financial Statements. However, the Company is unable to determine the
future impact, if any, at the date of approval of these Consolidated Financial Statements.
26. SUBSEQUENT EVENTS
There are no subsequent events.

Independent auditor’s report
To the shareholders of Pacific Edge Limited
Our opinion
In our opinion, the accompanying consolidated financial statements of Pacific Edge Limited (the
Company), including its subsidiaries (the Group), present fairly, in all material respects, the financial
position of the Group as at 31 March 2023, its financial performance and its cash flows for the year
then ended in accordance with New Zealand Equivalents to International Financial Reporting
Standards (NZ IFRS) and International Financial Reporting Standards (IFRS).
What we have audited
The Group's consolidated financial statements comprise:
● the consolidated balance sheet as at 31 March 2023;
● the consolidated statement of comprehensive income for the year then ended;
● the consolidated statement of changes in equity for the year then ended;
● the consolidated statement of cash flows for the year then ended; and
● the notes to the consolidated financial statements, which include significant accounting policies
and other explanatory information.
Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (New Zealand) (ISAs
(NZ)) and International Standards on Auditing (ISAs). Our responsibilities under those standards are
further described in the Auditor’s responsibilities for the audit of the consolidated financial statements
section of our report.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis
for our opinion.
Independence
We are independent of the Group in accordance with Professional and Ethical Standard 1 International
Code of Ethics for Assurance Practitioners (including International Independence Standards)
(New Zealand) (PES 1) issued by the New Zealand Auditing and Assurance Standards Board and the
International Code of Ethics for Professional Accountants (including International Independence
Standards) issued by the International Ethics Standards Board for Accountants (IESBA Code), and we
have fulfilled our other ethical responsibilities in accordance with these requirements.
Our firm carries out other services for the Group in the areas of half year review procedures and with
providing other assurance services. The provision of these other services have not impaired our
independence as auditor of the Group.
Key audit matters
Key audit matters are those matters that, in our professional judgement, were of most significance in
our audit of the consolidated financial statements of the current year. These matters were addressed
in the context of our audit of the consolidated financial statements as a whole, and in forming our
opinion thereon, and we do not provide a separate opinion on these matters.
PricewaterhouseCoopers, PwC Centre, 60 Cashel Street, PO Box 13-244, Christchurch 8141 New Zealand
T: +64 3 374 3000, www.pwc.co.nz
36

PwC
Description of the key audit matter
How our audit addressed the key audit
matter
Determining the timing of revenue recognition for
US revenue
As disclosed in Note 5 of the consolidated financial
statements, the timing of revenue recognition for US
based revenue varies by revenue stream between
completion of the Cxbladder test and receipt of cash.
The Company has three material United States (US)
revenue streams:
1. Coverage via Centers for Medicare and Medicaid
Services (CMS) and Medicare Advantage;
2. Tests performed for Kaiser Permanente; and
3. Other private insurance.
In July 2020, the Company received Local Coverage
Determination (“LCD”) and Local Coverage Article
(LCA) for CMS. This determination created a set
price for the Company’s tests of US$760 per test
from July 2020, and established a clear transaction
price for the tests. This transaction price, along with a
history of payment, satisfies the NZ IFRS
requirement for revenue recognition. On 29 July
2022, the company became aware of the proposed
changes to the LCD/LCA by Novitas. This has the
potential to significantly change the reimbursement of
Cxbladder tests in the US as the tests represent a
significant portion of current Cxbladder testing
revenue. The LCD/LCA is still in place and the
Company continues to receive reimbursement in line
with the existing LCD/LCA. The uncertainty in respect
of future operations is disclosed in Note 25.
In the year ended 31 March 2023, the basis of
revenue recognition for Kaiser Permanente changed
to an accrual basis, in line with Medicare and
Medicare Advantage, from the cash basis in the prior
year. This is a change in accounting estimate and
has been disclosed in Note 5.
Accordingly, in the US derived revenue for tests
performed for CMS, Medicare Advantage and Kaiser
Permanente has been recognised in advance of cash
being received. Revenue for these customers is
recognised when the tests are performed.
All other US derived revenue is accounted for on a
cash receipt basis as disclosed in Note 5.
We determined this to be a key audit matter due to
the significance of the judgments applied by Directors
for revenue recognition and the potential impact of
changes in the proposed LCD/LCA.
Our audit procedures included the following:
We obtained an understanding of management’s
processes and controls for the CMS, Medicare
Advantage, Kaiser Permanente and Private
Insurance US revenue streams, including the
relevant controls at the external billing
reimbursements service organisation.
We obtained the SOC1 System and Organisation
Controls Report for the external billing reimbursement
service organisation, and evaluated the evidence
provided over the design and operating effectiveness
of the relevant controls.
We evaluated management’s determination of the
timing of revenue recognition by:
● Assessing the data supporting revenue
recognition for CMS and Medicare Advantage to
confirm that the transaction price can be
determined and collectability is probable;
● Obtaining management’s latest assessment,
correspondence and other information in relation
to the status of the proposed LCD/LCA;
● Assessing the data supporting the change in
accounting estimate for revenue recognition for
Kaiser Permanente;
● Assessing the data supporting revenue
recognition for other private insurance to confirm
that the transaction price and collectability is only
probable when cash is received;
● Performing subsequent receipt testing to validate
the probability of collection of the year end
receivables and performing look back
procedures over the prior year receivable to test
collection rates; and
● Evaluated whether revenue has been recognised
appropriately in accordance with NZ IFRS 15.
We have no matters to report from the procedures
performed above.
37

PwC
Our audit approach
Overview
Overall group materiality: approximately $718,000, which represents 2.5% of
(loss)/earnings before interest, tax, depreciation and amortisation (EBITDA).
We chose (loss)/earnings before interest, tax, depreciation and amortisation
(EBITDA) as the benchmark because, in our view, it is the benchmark
against which the performance of the Group is most commonly measured by
users, and is a generally accepted benchmark.
We tailored the scope of our audit in order to perform sufficient work to
enable us to provide an opinion on the consolidated financial statements as
a whole, taking into account the structure of the Group, the accounting
processes and controls, and the industry in which the Group operates.
As reported above, we have one key audit matter, being:
● Determining the timing of revenue recognition for US revenue.
As part of designing our audit, we determined materiality and assessed the risks of material
misstatement in the consolidated financial statements. In particular, we considered where
management made subjective judgements; for example, in respect of significant accounting estimates
that involved making assumptions and considering future events that are inherently uncertain. As in all
of our audits, we also addressed the risk of management override of internal controls, including among
other matters, consideration of whether there was evidence of bias that represented a risk of material
misstatement due to fraud.
Materiality
The scope of our audit was influenced by our application of materiality. An audit is designed to obtain
reasonable assurance about whether the consolidated financial statements are free from material
misstatement. Misstatements may arise due to fraud or error. They are considered material if,
individually or in aggregate, they could reasonably be expected to influence the economic decisions of
users taken on the basis of the consolidated financial statements.
Based on our professional judgement, we determined certain quantitative thresholds for materiality,
including the overall Group materiality for the consolidated financial statements as a whole as set out
above. These, together with qualitative considerations, helped us to determine the scope of our audit,
the nature, timing and extent of our audit procedures and to evaluate the effect of misstatements, both
individually and in aggregate, on the consolidated financial statements as a whole.
How we tailored our group audit scope
We tailored the scope of our audit in order to perform sufficient work to enable us to provide an opinion
on the consolidated financial statements as a whole, taking into account the structure of the Group, the
accounting processes and controls, and the industry in which the Group operates.
We selected transactions and balances to audit based on their materiality to the Group rather than
determining the scope of procedures to perform by auditing only specific subsidiaries or business
units.
38

PwC
Other information
The Directors are responsible for the other information. The other information comprises the information
included in the Annual report, but does not include the consolidated financial statements and our
auditor's report thereon. The Annual report is expected to be made available to us after the date of this
auditor's report.
Our opinion on the consolidated financial statements does not cover the other information and we will
not express any form of audit opinion or assurance conclusion thereon.
In connection with our audit of the consolidated financial statements, our responsibility is to read the
other information and, in doing so, consider whether the other information is materially inconsistent with
the consolidated financial statements or our knowledge obtained in the audit, or otherwise appears to be
materially misstated.
When we read the other information not yet received, if we conclude that there is a material
misstatement therein, we are required to communicate the matter to the Directors and use our
professional judgement to determine the appropriate action to take.
Responsibilities of the Directors for the consolidated financial statements
The Directors are responsible, on behalf of the Company, for the preparation and fair presentation of the
consolidated financial statements in accordance with NZ IFRS and IFRS, and for such internal control as
the Directors determine is necessary to enable the preparation of consolidated financial statements that
are free from material misstatement, whether due to fraud or error.
In preparing the consolidated financial statements, the Directors are responsible for assessing the
Group’s ability to continue as a going concern, disclosing, as applicable, matters related to going
concern and using the going concern basis of accounting unless the Directors either intend to liquidate
the Group or to cease operations, or have no realistic alternative but to do so.
Auditor’s responsibilities for the audit of the consolidated financial statements
Our objectives are to obtain reasonable assurance about whether the consolidated financial statements,
as a whole, are free from material misstatement, whether due to fraud or error, and to issue an auditor’s
report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a
guarantee that an audit conducted in accordance with ISAs (NZ) and ISAs will always detect a material
misstatement when it exists. Misstatements can arise from fraud or error and are considered material if,
individually or in the aggregate, they could reasonably be expected to influence the economic decisions
of users taken on the basis of these consolidated financial statements.
A further description of our responsibilities for the audit of the consolidated financial statements is
located at the External Reporting Board’s website at:
https://www.xrb.govt.nz/assurance-standards/auditors-responsibilities/audit-report-1/
This description forms part of our auditor’s report.
Who we report to
This report is made solely to the Company’s shareholders, as a body. Our audit work has been
undertaken so that we might state those matters which we are required to state to them in an auditor’s
report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume
responsibility to anyone other than the Company and the Company’s shareholders, as a body, for our
audit work, for this report or for the opinions we have formed.
39

PwC
The engagement partner on the audit resulting in this independent auditor’s report is Maxwell John
Dixon.
For and on behalf of:
Chartered Accountants Christchurch
24 May 2023
40

PACIFIC EDGE LIMITED CONSOLIDATED FINANCIAL STATEMENTS 2023
41
COMPANY DIRECTORY
As at 31 March 2023
Issued Capital
810,365,218 Ordinary Shares
Registered Office
Level 10, Otago House
Cnr Moray Place and Princes Street
Dunedin
Directors
C. Gallaher – Chairman
B. Williams – Deputy Chairman
A. Masfen
S. Park
A. Stove
M. Green
A. Barclay
Chief Executive Officer
Peter Meintjes
Chief Financial Officer
Grant Gibson
Nature of Business
Research, develop and commercialise new
diagnostic and prognostic tools for the early
detection and management of cancers.
Auditors
PricewaterhouseCoopers
Christchurch
Bankers
Bank of New Zealand
Dunedin
ANZ
Dunedin
Kiwibank
Dunedin
Westpac
Dunedin
Wells Fargo
San Francisco
Solicitors
Anderson Lloyd
Level 10, Otago House
Cnr Moray Place and Princes Street
Dunedin
Securities Registrar
Link Market Services Limited
138 Tancred Street
Ashburton
Company Number
1119032
Date of Incorporation
27 February 2001

PACIFIC EDGE COMMUNICATIONS

Websites
www.pacificedgedx.com
www.cxbladder.com
Facebook
www.facebook.com/PacificEdgeLtd
www.facebook.com/Cxbladder

Twitter
@PacificEdgeLtd
@Cxbladder

LinkedIn
www.linkedin.com/company/pacific-edge-ltd

87 St David Street, PO Box 56, Dunedin, New Zealand
P +64 3 479 5800 F +64 3 479 5801
www.pacificedge.co.nz

---

Template
Results announcement
(for Equity Security issuer/Equity and Debt Security issuer)
Updated as at 17 October 2019


Results for announcement to the market
Name of issuer Pacific Edge Limited
Reporting Period 12 months to 31 March 2023
Previous Reporting Period 12 months to 31 March 2022
Currency NZD (New Zealand Dollar)
Amount (000s) Percentage change
Revenue from continuing
operations
$19,616 71% Increase
Total Revenue $26,124 88% Increase
Net profit/(loss) from
continuing operations
($26,965) 36% Decrease
Total net profit/(loss) ($26,965) 36% Decrease
Interim/Final Dividend
Amount per Quoted Equity
Security
The Company does not propose to pay dividends to
shareholders
Imputed amount per Quoted
Equity Security
Not Applicable
Record Date Not Applicable
Dividend Payment Date Not Applicable
Current period Prior comparable period
Net tangible assets per
Quoted Equity Security
$0.101 $0.133
A brief explanation of any of
the figures above necessary
to enable the figures to be
understood
The Results Announcement should be read in conjunction with
the audited consolidated financial statements for the year ended
31 March 2023, the results presentation and commentary, all of
which have been released with this Results Announcement.
Authority for this announcement
Name of person authorised
to make this announcement
Peter Meintjes
Contact person for this
announcement
Peter Meintjes
Contact phone number
+64 (3) 479 5800

Contact email address peter.meintjes@pelnz.com
Date of release through MAP 25/05/2023

Audited financial statements accompany this announcement.